<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="psp412742" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">CPT Pharmacometrics Syst Pharmacol</journal-id><journal-id journal-id-type="iso-abbrev">CPT Pharmacometrics Syst Pharmacol</journal-id><journal-id journal-id-type="pmc-domain-id">2038</journal-id><journal-id journal-id-type="pmc-domain">cptpsp</journal-id><journal-id journal-id-type="publisher-id">PSP4</journal-id><journal-title-group><journal-title>CPT: Pharmacometrics &amp; Systems Pharmacology</journal-title></journal-title-group><issn pub-type="epub">2163-8306</issn><publisher><publisher-name>Wiley</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC8752110</article-id><article-id pub-id-type="pmcid-ver">PMC8752110.1</article-id><article-id pub-id-type="pmcaid">8752110</article-id><article-id pub-id-type="pmcaiid">8752110</article-id><article-id pub-id-type="pmid">34730282</article-id><article-id pub-id-type="doi">10.1002/psp4.12737</article-id><article-id pub-id-type="publisher-id">PSP412737</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Research</subject><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group></subj-group></article-categories><title-group><article-title>Physiologically based pharmacokinetic modeling for dose optimization of quinine&#8211;phenobarbital coadministration in patients with cerebral malaria</article-title><alt-title alt-title-type="right-running-head">Predicted quinine&#8211;phenobarbital doses in malaria</alt-title><alt-title alt-title-type="left-running-head">SAE&#8208;HENG et al.</alt-title></title-group><contrib-group><contrib id="psp412737-cr-0001" contrib-type="author"><name name-style="western"><surname>Sae&#8208;heng</surname><given-names initials="T">Teerachat</given-names></name><xref rid="psp412737-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="psp412737-cr-0002" contrib-type="author"><name name-style="western"><surname>Rajoli</surname><given-names initials="RKR">Rajith Kumar Reddy</given-names></name><xref rid="psp412737-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="psp412737-cr-0003" contrib-type="author"><name name-style="western"><surname>Siccardi</surname><given-names initials="M">Marco</given-names></name><xref rid="psp412737-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="psp412737-cr-0004" contrib-type="author"><name name-style="western"><surname>Karbwang</surname><given-names initials="J">Juntra</given-names></name><xref rid="psp412737-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="psp412737-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="psp412737-cr-0005" contrib-type="author" corresp="yes"><name name-style="western"><surname>Na&#8208;Bangchang</surname><given-names initials="K">Kesara</given-names></name><xref rid="psp412737-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="psp412737-aff-0003" ref-type="aff">
<sup>3</sup>
</xref><address><email>kesaratmu@yahoo.com</email></address></contrib></contrib-group><aff id="psp412737-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Center of Excellence in Pharmacology and Molecular Biology of Malaria and Cholangiocarcinoma</named-content>
<named-content content-type="organisation-division">Chulabhorn International College</named-content>
<institution>Thammasat University (Rangsit Campus)</institution>
<city>Pathumthani</city>
<country country="TH">Thailand</country>
</aff><aff id="psp412737-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Department of Molecular and Clinical Pharmacology</named-content>
<institution>University of Liverpool</institution>
<city>Liverpool</city>
<country country="GB">UK</country>
</aff><aff id="psp412737-aff-0003">
<label>
<sup>3</sup>
</label>
<named-content content-type="organisation-division">Drug Discovery and Development Center</named-content>
<named-content content-type="organisation-division">Office of Advanced Science and Technology</named-content>
<institution>Thammasat University (Rangsit Campus)</institution>
<city>Pathumthani</city>
<country country="TH">Thailand</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>
Kesara Na&#8208;Bangchang, Chulabhorn International College of Medicine, Thammasat University (Rangsit Campus), 99 Moo 18, Phaholyothin Road, Klongluang District, Pathumthani 12121, Thailand.<break/>
Email: <email>kesaratmu@yahoo.com</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>23</day><month>11</month><year>2021</year></pub-date><pub-date pub-type="ppub"><month>1</month><year>2022</year></pub-date><volume>11</volume><issue seq="110">1</issue><issue-id pub-id-type="pmc-issue-id">398256</issue-id><issue-id pub-id-type="doi">10.1002/psp4.v11.1</issue-id><fpage>104</fpage><lpage>115</lpage><history><date date-type="rev-recd"><day>04</day><month>10</month><year>2021</year></date><date date-type="received"><day>17</day><month>6</month><year>2021</year></date><date date-type="accepted"><day>12</day><month>10</month><year>2021</year></date></history><pub-history><event event-type="pmc-release"><date><day>01</day><month>01</month><year>2022</year></date></event><event event-type="pmc-live"><date><day>14</day><month>01</month><year>2022</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2022-01-15 00:16:41.073"><day>15</day><month>01</month><year>2022</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">&#169; 2021 The Authors. <italic toggle="yes">CPT: Pharmacometrics &amp; Systems Pharmacology</italic> published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non&#8208;commercial and no modifications or adaptations are made.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="PSP4-11-104.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:PSP4-11-104.pdf"/><abstract id="psp412737-abs-0001"><title>Abstract</title><p>Patients with cerebral malaria with polymorphic <italic toggle="yes">Cytochrome P450 2C19</italic> (<italic toggle="yes">CYP2C19</italic>) genotypes who receive concurrent treatment with quinine are at risk of inadequate or toxic therapeutic drug concentrations due to metabolic drug interactions. The study aimed to predict the potential dose regimens of quinine when coadministered with phenobarbital in adult patients with cerebral malaria and complications (e.g., lactic acidosis and acute renal failure) and concurrent with seizures and acute renal failure who carry wild&#8208;type and polymorphic <italic toggle="yes">CYP2C19</italic>. The whole&#8208;body physiologically based pharmacokinetic (PBPK) models for quinine, phenobarbital, and quinine&#8211;phenobarbital coadministration were constructed based on the previously published information using Simbiology&#174;. Four published articles were used for model validation. A total of 100 virtual patients were simulated based on the 14&#8208;day and 3&#8208;day courses of treatment. using the drug&#8211;drug interaction approach. The predicted results were within 15% of the observed values. Standard phenobarbital dose, when administered with quinine, is suitable for all groups with single or continuous seizures regardless of <italic toggle="yes">CYP2C19</italic>&#160;genotype, renal failure, and lactic acidosis. Dose adjustment based on area under the curve ratio provided inappropriate quinine concentrations. The recommended dose of quinine when coadministered with phenobarbital based on the PBPK model for all groups is a loading dose of 2000&#160;mg intravenous (i.v.) infusion rate 250&#160;mg/h followed by 1200&#160;mg i.v. rate 150&#160;mg/h. The developed PBPK models are credible for further simulations. Because the predicted quinine doses in all groups were similar regardless of the <italic toggle="yes">CYP2C19</italic>&#160;genotype, genotyping may not be required.</p></abstract><funding-group><award-group id="funding-0001"><funding-source>Thammasat University under the project Center of Excellence in Pharmacology and Molecular Biology of Malaria and Cholangiocarcinoma</funding-source><award-id>1/2556</award-id></award-group><award-group id="funding-0002"><funding-source><institution-wrap><institution>National Research Council of Thailand
</institution><institution-id institution-id-type="doi">10.13039/501100004704</institution-id></institution-wrap></funding-source><award-id>45/2561</award-id></award-group><award-group id="funding-0003"><funding-source>National Research Council of Thailand under the Research Team Promotion</funding-source><award-id>820/2563</award-id></award-group><award-group id="funding-0004"><funding-source><institution-wrap><institution>Thammasat University
</institution><institution-id institution-id-type="doi">10.13039/501100005790</institution-id></institution-wrap></funding-source></award-group></funding-group><counts><fig-count count="5"/><table-count count="2"/><page-count count="12"/><word-count count="7081"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>January 2022</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.7.0 mode:remove_FC converted:11.01.2022</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="psp412737-cit-1001"><string-name name-style="western"><surname>Sae&#8208;heng</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Rajoli</surname><given-names>RKR</given-names></string-name>, <string-name name-style="western"><surname>Siccardi</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Karbwang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Na&#8208;Bangchang</surname><given-names>K</given-names></string-name>. <article-title>Physiologically based pharmacokinetic modeling for dose optimization of quinine&#8211;phenobarbital coadministration in patients with cerebral malaria</article-title>. <source>CPT Pharmacometrics Syst Pharmacol</source>. <year>2022</year>;<volume>11</volume>:<fpage>104</fpage>&#8211;<lpage>115</lpage>. doi:<pub-id pub-id-type="doi">10.1002/psp4.12737</pub-id><pub-id pub-id-type="pmcid">PMC8752110</pub-id><pub-id pub-id-type="pmid">34730282</pub-id></mixed-citation>
</p><fn-group id="psp412742-ntgp-0001"><fn fn-type="funding" id="psp412737-note-0001"><p>
<bold>Funding information</bold>
</p><p>The study received funding from Thammasat University under the project Center of Excellence in Pharmacology and Molecular Biology of Malaria and Cholangiocarcinoma (no. 1/2556, dated October 12, 2013) and the National Research Council of Thailand (no. 45/2561, dated September 10, 2018). K.N. is supported by the National Research Council of Thailand under the Research Team Promotion grant (Grant National Research Council of Thailand [NRCT] 820/2563, dated November 12, 2020). J.K. receives research support from Thammasat University (Bualuang Association of South East Asian Nations [ASEAN] Chair Professor).</p></fn></fn-group></notes></front><body id="psp412737-body-0001"><p>
<boxed-text position="anchor" content-type="box" orientation="portrait"><caption><title>Study Highlights</title></caption><p>
<list list-type="simple" id="psp412737-list-0001"><list-item><p>
<bold>WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?</bold>
</p></list-item></list>
</p><p>Quinine is a drug of choice for severe malaria, including cerebral malaria, in cases when injectable artesunate and/or parenteral artemether are not available. Phenobarbital is the standard treatment for cerebral malaria with concurrent seizures. Patients with cerebral malaria with polymorphic <italic toggle="yes">Cytochrome P450 2C19 (CYP2C19)</italic>&#160;genotypes who receive concurrent treatment with quinine are at risk of inadequate or toxic therapeutic drug concentrations as a result of metabolic drug interactions.
<list list-type="simple" id="psp412737-list-0002"><list-item><p>
<bold>WHAT QUESTION DID THIS STUDY ADDRESS?</bold>
</p></list-item></list>
</p><p>Does patients carrying polymorphic <italic toggle="yes">CYP2C19</italic> with cerebral malaria with concurrent seizures require quine&#8208;phenobarbital co&#8208;administered dose optimization? If so, what are the optimal dose regimens of both drugs when coadministered? 
<list list-type="simple" id="psp412737-list-0003"><list-item><p>
<bold>WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE?</bold>
</p></list-item></list>
</p><p>The recommended dose of quinine and phenobarbital coadministration with phenobarbital based on the physiologically based pharmacokinetic (PBPK) model for all patients is a loading dose of 2000&#160;mg i.v. infusion rate 250&#160;mg/h followed by 1200&#160;mg i.v. rate 150&#160;mg/h. <italic toggle="yes">CYP2C19</italic>&#160;genotyping and phenobarbital dose optimization are not required when coadministered with quinine.
<list list-type="simple" id="psp412737-list-0004"><list-item><p>
<bold>HOW MIGHT THIS CHANGE DRUG DISCOVERY, DEVELOPMENT, AND/OR THERAPEUTICS?</bold>
</p></list-item></list>
</p><p>The developed PBPK models are credible for further simulations of optimal dose regimens of quinine in patients with cerebral malaria with concurrent seizures and complications.</p></boxed-text>
</p><sec id="psp412737-sec-0002"><title>INTRODUCTION</title><p>Cerebral malaria remains a high burden neurological problem not only in children aged younger than 5 years but also in adults.<xref rid="psp412737-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref>, <xref rid="psp412737-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref>, <xref rid="psp412737-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref> Quinine is a drug of choice for severe malaria, including cerebral malaria in cases when injectable artesunate and/or parenteral artemether are not available (the recommended regimen is a loading dose of 20&#160;mg/kg salt intravenous [i.v.] infusion for 4 h followed by 10&#160;mg&#160;kg<sup>&#8722;1</sup> salt i.v. infusion for 4 h given every 8 h).<xref rid="psp412737-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref> Phenobarbital, a cost&#8208;effective antiepileptic drug, is the standard treatment for cerebral malaria with concurrent seizures (the recommended regimen is a loading dose of 15&#160;mg/kg given i.v. infusion for 30&#160;min followed by 1&#8211;3&#160;mg&#160;kg<sup>&#8722;1</sup> given i.v. infusion for 30&#160;min every 12 h).<xref rid="psp412737-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref>, <xref rid="psp412737-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref> Phenobarbital&#8208;induced severe cutaneous adverse reactions are, however, of critical concern for clinical use of this drug.<xref rid="psp412737-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref> Information on the contribution of host genetics on such reactions in adult patients with cerebral malaria with concurrent seizures has been limited. Because phenobarbital induces the xenobiotic drug&#8208;metabolizing cytochrome P450 (CYP450) enzymes, the situation is further complicated when it is coadministered with drugs that are also metabolized by CYP450 enzymes. Phenobarbital is metabolized mainly in the livers by the polymorphic CYP450 isoforms: CYP2C9<xref rid="psp412737-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref>, <xref rid="psp412737-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref> (fraction of metabolized [f<sub>m</sub>] of CYP2C9 or f<sub>m,CYP2C9</sub>&#160;=&#160;0.1) and CYP2C19<xref rid="psp412737-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref>, <xref rid="psp412737-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref> (f<sub>m,CYP2C19</sub>&#160;=&#160;0.9). Quinine, on the other hand, is metabolized by CYP3A4 and uridine diphosphate&#8208;glucuronosyltransferase1A1 (UGT1A1)<xref rid="psp412737-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref> (f<sub>m,CYP3A4</sub>&#160;=&#160;0.44 and f<sub>m,UGT1A1</sub>&#160;=&#160;0.56). The activities of both CYP3A4 and UGT1A1 enzymes are induced by phenobarbital.<xref rid="psp412737-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref>, <xref rid="psp412737-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref> In addition, phenobarbital also induces CYP1A2, CYP2B1, CYP2B2, CYP2B6, CYP2C9, UGT1A4, UGT1A8, and UGT1A9.<xref rid="psp412737-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref>, <xref rid="psp412737-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref> Patients with cerebral malaria with polymorphic <italic toggle="yes">CYP2C19</italic>&#160;genotypes (altered phenobarbital clearance) who receive concurrent treatment with quinine are, therefore, at risk of inadequate or toxic therapeutic drug concentrations as a result of metabolic drug interactions. In addition, quinine is a narrow therapeutic drug (therapeutic range 10&#8211;20&#160;mg&#160;L<sup>&#8722;1</sup>, therapeutic index 2).<xref rid="psp412737-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref>&#160;To our knowledge, there have been a few reports on the optimal phenobarbital dose for patients with epilepsy,<xref rid="psp412737-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref>, <xref rid="psp412737-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref> but not for patients with cerebral malaria with seizures who carry polymorphic <italic toggle="yes">CYP2C19</italic> as well as the wild&#8208;type genotypes. Also, the optimal dose(s) of quinine when coadministered with phenobarbital has never been reported in this group of patients. This is of concern as approximately 17.3% of adult patients with malaria had severe malaria, where 70.7% of the patients developed convulsions and the overall mortality rate was up to 14% of severe malaria cases.<xref rid="psp412737-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref>
</p><p>Physiologically based pharmacokinetic (PBPK) modeling and simulation are accepted by various regulatory authorities as a promising tool to support dose optimization in the clinical phase of drug development, particularly for the investigation of drug&#8211;drug interactions (DDIs) and non&#8208;DDIs.<xref rid="psp412737-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref>&#160;The present study aimed to apply PBPK modeling and simulation for the optimization of quinine and phenobarbital coadministration in adult patients with cerebral malaria with concurrent seizures. The optimal dose(s) was predicted with consideration of genetic polymorphisms of CYP2C19, malarial complications (i.e., lactic acidosis and acute renal failure), and the propensity of DDIs.</p></sec><sec sec-type="methods" id="psp412737-sec-0003"><title>METHODS</title><sec id="psp412737-sec-0004"><title>Model construction</title><p>Whole&#8208;body PBPK models for quinine and phenobarbital (alone and coadministration) were constructed based on the previously published information<xref rid="psp412737-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref>, <xref rid="psp412737-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref> using Simbiology<sup>&#174;</sup> (version 5.8.2), the product of MATLAB<sup>&#174;</sup> (version 2019a; MathWorks, Natick, MA). The physicochemical and biochemical properties (model parameters) of each drug, including human physiological parameters, were obtained from the published articles and are available in the supplementary material of this article.<xref rid="psp412737-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref>, <xref rid="psp412737-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref>, <xref rid="psp412737-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref>, <xref rid="psp412737-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref>, <xref rid="psp412737-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref>, <xref rid="psp412737-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref>, <xref rid="psp412737-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref>, <xref rid="psp412737-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref>, <xref rid="psp412737-bib-0026" ref-type="bibr">
<sup>26</sup>
</xref>, <xref rid="psp412737-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref>, <xref rid="psp412737-bib-0028" ref-type="bibr">
<sup>28</sup>
</xref>, <xref rid="psp412737-bib-0029" ref-type="bibr">
<sup>29</sup>
</xref>, <xref rid="psp412737-bib-0030" ref-type="bibr">
<sup>30</sup>
</xref>, <xref rid="psp412737-bib-0031" ref-type="bibr">
<sup>31</sup>
</xref>, <xref rid="psp412737-bib-0032" ref-type="bibr">
<sup>32</sup>
</xref>, <xref rid="psp412737-bib-0033" ref-type="bibr">
<sup>33</sup>
</xref>, <xref rid="psp412737-bib-0034" ref-type="bibr">
<sup>34</sup>
</xref>, <xref rid="psp412737-bib-0035" ref-type="bibr">
<sup>35</sup>
</xref> Because quinine is a CYP3A4 inhibitor, the inhibitor constant was taken into account for model construction. Model assumptions included, blood&#8208;flow limited, absence of enterohepatic recirculation, and absence of 3&#8208;hydroxyquinine (metabolite) on quinine disposition.</p></sec><sec id="psp412737-sec-0005"><title>Model validation</title><p>Four published articles for quinine<xref rid="psp412737-bib-0032" ref-type="bibr">
<sup>32</sup>
</xref>, <xref rid="psp412737-bib-0036" ref-type="bibr">
<sup>36</sup>
</xref>, <xref rid="psp412737-bib-0037" ref-type="bibr">
<sup>37</sup>
</xref>, <xref rid="psp412737-bib-0038" ref-type="bibr">
<sup>38</sup>
</xref> and one article for phenobarbital<xref rid="psp412737-bib-0039" ref-type="bibr">
<sup>39</sup>
</xref> were used for model validation. The published data were extracted using Plot digitizer<sup>&#174;</sup> version 2.6.8 (Free Software Foundation, Inc., Boston, MA). The area under the plasma concentration&#8211;time curve (AUC) was calculated using the trapezoidal rule. The simulated results from the developed models were compared against the published data using the accepted criterion, that is, absolute average&#8208;fold errors (AAFEs) of &#177;2&#8208;fold.<xref rid="psp412737-bib-0040" ref-type="bibr">
<sup>40</sup>
</xref> However, as quinine is a drug with a narrow therapeutic index, the AAFE used in this article was reduced to &#177;1.25&#8208;fold. The following is the mathematical equation for AAFEs:<disp-formula id="psp412737-disp-0001"><mml:math id="jats-math-1" display="block"><mml:mrow><mml:mtext>AAFEs</mml:mtext><mml:mo>=</mml:mo><mml:msup><mml:mn>10</mml:mn><mml:mrow><mml:msubsup><mml:mo>&#8721;</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>&#8230;</mml:mi><mml:mo>,</mml:mo><mml:mi>n</mml:mi></mml:mrow><mml:mi>n</mml:mi></mml:msubsup><mml:mrow><mml:mfenced close=")" open="("><mml:mfenced close="|" open="|" separators=""><mml:mrow><mml:mi>log</mml:mi><mml:mfrac><mml:mtext>prediction</mml:mtext><mml:mtext>observation</mml:mtext></mml:mfrac></mml:mrow></mml:mfenced></mml:mfenced><mml:mo stretchy="false">/</mml:mo><mml:mi>n</mml:mi></mml:mrow></mml:mrow></mml:msup></mml:mrow></mml:math></disp-formula>where <italic toggle="yes">n</italic> is the number of observed pharmacokinetic parameters, the prediction is the simulated results from the developed model, and the observation is the published clinical data.</p></sec><sec id="psp412737-sec-0006"><title>Sensitivity analysis</title><p>Sensitivity analysis was performed to determine the effect of the changes in model parameters on the clearance during the first 72&#160;h following the i.v. regimen of phenobarbital and quinine&#8211;phenobarbital coadministration (DDI model). The model parameters for sensitivity analysis of the phenobarbital included a fraction of unbound phenobarbital (<italic toggle="yes">f</italic>
<sub>u</sub>), acid dissociation constant (pKa) of phenobarbital, LogP of phenobarbital, blood&#8208;to&#8208;plasma ratio (<italic toggle="yes">R</italic>
<sub>bp</sub>) of phenobarbital, <italic toggle="yes">f</italic>
<sub>m,CYP2C19</sub>, and <italic toggle="yes">f</italic>
<sub>m,CYP2C9</sub>, maximal effect at high concentrations (E<sub>max</sub>) of CYP2C19, half&#8208;maximal effective concentrations (EC<sub>50</sub>) of CYP2C19, and hepatic blood flow (Q<sub>hv</sub>). The model parameters for quinine (quinine&#8211;phenobarbital model) included f<sub>u</sub> of quinine, acid dissociation constant (pKa) of quinine, LogP of quinine, <italic toggle="yes">R</italic>
<sub>bp</sub> of quinine, <italic toggle="yes">f</italic>
<sub>m,CYP3A4</sub>, <italic toggle="yes">f</italic>
<sub>m,UGT1A1</sub>, E<sub>max</sub> of CYP2C19, UGT1A1, CYP3A4, and EC<sub>50</sub> of CYP2C19, UGT1A1, CYP3A4, Q<sub>hv</sub>, and the relative effect of <italic toggle="yes">CYP2C19</italic> polymorphisms (wild&#8208;type, <italic toggle="yes">2C19*1</italic>/<italic toggle="yes">*2</italic>, <italic toggle="yes">2C19*1</italic>/<italic toggle="yes">*3</italic>, <italic toggle="yes">2C19*2</italic>/<italic toggle="yes">*2</italic>, and <italic toggle="yes">2C19*3</italic>/<italic toggle="yes">*3</italic>). The effect of the changes in model parameters on the clearance was determined by the change of each model parameter within &#177;20%. The following is the mathematical equation for sensitivity analysis:<disp-formula id="psp412737-disp-0002"><mml:math id="jats-math-2" display="block"><mml:mrow><mml:mtext>Sensitivity coefficient</mml:mtext><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mo>%</mml:mo><mml:mi mathvariant="normal">&#8711;</mml:mi><mml:mi>Y</mml:mi></mml:mrow><mml:mrow><mml:mo>%</mml:mo><mml:mi mathvariant="normal">&#8711;</mml:mi><mml:mi>X</mml:mi></mml:mrow></mml:mfrac></mml:mrow></mml:math></disp-formula>where %&#8711;Y is the percent change of the clearance, and <mml:math id="jats-math-3"><mml:mrow><mml:mo>%</mml:mo><mml:mi mathvariant="normal">&#8711;</mml:mi><mml:mi>X</mml:mi></mml:mrow></mml:math> is the percent change of the model parameters.</p></sec><sec id="psp412737-sec-0007"><title>Virtual population</title><p>A total of 100 virtual patients (50&#160;males and 50 females aged 18&#8211;60&#160;years and weighing 60&#160;kg during the fasting state) were simulated in (i) seizure patients with polymorphic <italic toggle="yes">CYP2C19</italic> (phenobarbital model), (ii) patients with cerebral malaria (quinine model), (iii) patients with cerebral malaria with concurrent seizures and polymorphic <italic toggle="yes">CYP2C19</italic> (DDI model), and (iv) patients with cerebral malaria with concurrent seizures and acute renal failure (corrected with lactic acidosis) and polymorphic <italic toggle="yes">CYP2C19</italic>. The intrinsic clearance of phenobarbital in each genotype was obtained from the published clinical data for the wild&#8208;type <italic toggle="yes">CYP2C19*1</italic>/<italic toggle="yes">*1</italic> (extensive metabolizer [EM]),<xref rid="psp412737-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref>
<italic toggle="yes">CYP2C19*1</italic>/<italic toggle="yes">*2</italic> (intermediate metabolizer [IM]), and <italic toggle="yes">CYP19*1</italic>/<italic toggle="yes">*3</italic>, <italic toggle="yes">CYP2C19*2</italic>/<italic toggle="yes">*2</italic>, or <italic toggle="yes">CYP2C19*3</italic>/<italic toggle="yes">*3</italic> (poor metabolizer [PM]).<xref rid="psp412737-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref> The intrinsic clearance values in <italic toggle="yes">CYP2C19*1</italic>/<italic toggle="yes">*2</italic> (IM) and <italic toggle="yes">CYP2C2C19*1</italic>/<italic toggle="yes">*3</italic> or <italic toggle="yes">CYP2C19*2</italic>/<italic toggle="yes">*2</italic> or <italic toggle="yes">CYP2C19*3</italic>/<italic toggle="yes">*3</italic> (PM)<xref rid="psp412737-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref> were estimated as a relative clearance compared with wild&#8208;type. Acute renal failure or acute kidney injury (AKI) was classified based on the risk, injury, failure, loss of kidney function and end&#8208;stage kidney disease (RIFLE) criteria, that is, AKI (&#8804;25% decrease of estimated glomerular filtration rate [eGFR]), RIFLE&#8208;R (risk; &gt;25%&#8211;50% decrease of eGFR), RIFLE&#8208;I (injury; &gt; 50%&#8211;75% decrease of eGFR), or RIFLE&#8208;F (failure; &gt;75% decrease of eGFR).<xref rid="psp412737-bib-0041" ref-type="bibr">
<sup>41</sup>
</xref>
</p></sec><sec id="psp412737-sec-0008"><title>Quinine dose regimen used in simulations</title><p>The standard regimen of quinine for severe malaria is the loading dose of 20&#160;mg&#160;kg<sup>&#8722;1</sup> (1000&#160;mg base total dose for an average body weight of 60&#160;kg) i.v. infusion for 4&#160;h followed by the maintenance dose of 10&#160;mg&#160;kg<sup>&#8722;1</sup> (500&#160;mg base total dose for an average body weight of 60&#160;kg) i.v. infusion for 4&#160;h given three times daily for 72&#160;h (assuming that the patients respond to quinine treatment).<xref rid="psp412737-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref>
</p></sec><sec id="psp412737-sec-0009"><title>DDI model simulations</title><sec id="psp412737-sec-0010"><title>Simulation based on standard DDI study approach</title><p>For the standard DDI study approach, plasma concentration&#8211;time profiles of phenobarbital and quinine following the coadministration of the standard dose regimen of phenobarbital and quinine were simulated. Phenobarbital is given at 1.5&#160;mg&#160;kg<sup>&#8722;1</sup>&#160;day<sup>&#8722;1</sup> (1&#8211;3&#160;mg&#160;kg<sup>&#8722;1</sup>&#160;day<sup>&#8722;1</sup>) or 90&#160;mg total dose for an average body weight of 60&#160;kg with i.v. infusion for 30&#160;min for 17 consecutive days. The standard dose regimen of quinine for 3 days (described previously) was given on day 14 of phenobarbital administration when steady&#8208;state plasma concentration was achieved.</p></sec><sec id="psp412737-sec-0011"><title>Simulation based on actual clinical approach</title><p>For the PBPK simulation based on an actual clinical use approach, two simulated scenarios were applied with the total simulation time of 72&#160;h. Scenario I applies to patients who have only a single seizure; phenobarbital (15&#160;mg&#160;kg<sup>&#8722;1</sup> or 900&#160;mg total dose for an average body weight of 60 kg with i.v. infusion for 30&#160;min) is given as a single dose 6&#160;h after the first dose of quinine (average time of occurrence of seizure after admission).<xref rid="psp412737-bib-0042" ref-type="bibr">
<sup>42</sup>
</xref>&#160;Scenario II applies to patients who have continuous seizures; phenobarbital at a loading dose of 15&#160;mg&#160;kg<sup>&#8722;1</sup> or 900&#160;mg total dose for an average body weight of 60 kg with i.v. infusion for 30&#160;min followed by the maintenance dose of 1.5&#160;mg&#160;kg<sup>&#8722;1</sup>&#160;day<sup>&#8722;1</sup> (1&#8211;3&#160;mg&#160;kg<sup>&#8722;1</sup>&#160;day<sup>&#8722;1</sup>) or 90&#160;mg total dose for an average body weight of 60 kg with i.v. infusion for 30&#160;min<xref rid="psp412737-bib-0042" ref-type="bibr">
<sup>42</sup>
</xref> is given every 24&#160;h, starting 6&#160;h after the first dose of quinine until 72&#160;h. The time of simulation and seizure frequency was based on a previous clinical report.<xref rid="psp412737-bib-0043" ref-type="bibr">
<sup>43</sup>
</xref>&#160;The predicted optimal dosage regimens were presented as the amount of quinine base.</p></sec></sec><sec id="psp412737-sec-0012"><title>Criteria for optimal dose regimens</title><p>All regimens for quinine and phenobarbital were evaluated based on the criteria for optimal dose regimens. The optimal dose regimens of quinine for adult patients with cerebral malaria with seizures were proposed based on the therapeutic range of quinine, that is, maximal plasma concentration (C<sub>max</sub>) &#8804;20&#160;mg&#160;L<sup>&#8722;1</sup> and minimal plasma concentration (C<sub>min</sub>) &#8805;10&#160;mg&#160;L<sup>&#8722;1</sup>.<xref rid="psp412737-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref>&#160;The optimal dosage of phenobarbital was proposed based on the therapeutic range of phenobarbital, that is, C<sub>max</sub> &#8804;40&#160;mg&#160;L<sup>&#8722;1</sup>,<xref rid="psp412737-bib-0044" ref-type="bibr">
<sup>44</sup>
</xref> and C<sub>min</sub> &#8805;15&#160;mg&#160;L<sup>&#8722;1</sup>.<xref rid="psp412737-bib-0042" ref-type="bibr">
<sup>42</sup>
</xref>&#160;The predicted pharmacokinetic parameters are presented as mean &#177; standard deviation (SD).</p></sec></sec><sec sec-type="results" id="psp412737-sec-0013"><title>RESULTS</title><sec id="psp412737-sec-0014"><title>Model validation</title><p>The AAFEs for overall (both quinine and phenobarbital), quinine, and phenobarbital ranged from 1.08 &#177; 0.07,<xref rid="psp412737-bib-0036" ref-type="bibr">
<sup>36</sup>
</xref> 1.07 &#177; 0.076,<xref rid="psp412737-bib-0032" ref-type="bibr">
<sup>32</sup>
</xref>, <xref rid="psp412737-bib-0036" ref-type="bibr">
<sup>36</sup>
</xref>, <xref rid="psp412737-bib-0037" ref-type="bibr">
<sup>37</sup>
</xref>, <xref rid="psp412737-bib-0038" ref-type="bibr">
<sup>38</sup>
</xref> and 1.13,<xref rid="psp412737-bib-0039" ref-type="bibr">
<sup>39</sup>
</xref> respectively. The overall AAFEs were within accepted ranges<xref rid="psp412737-bib-0040" ref-type="bibr">
<sup>40</sup>
</xref> (Table&#160;<xref rid="psp412737-sup-0001" ref-type="supplementary-material">S1</xref>). In addition, the overall errors were within 20% of the published data. The virtual predictive checks between the predicted results and published data are shown in the supplementary material file (Figure&#160;<xref rid="psp412737-sup-0017" ref-type="supplementary-material">S1</xref>).</p></sec><sec id="psp412737-sec-0015"><title>Sensitivity analysis</title><p>None of the sensitivity coefficient analysis values for phenobarbital clearance (phenobarbital model) in the wild&#8208;type <italic toggle="yes">CYP2C19</italic>EM, CYP<italic toggle="yes">2C19*1</italic>/<italic toggle="yes">*3</italic>PM, and <italic toggle="yes">CYP2C19</italic>PM were lower than 1 (Figure&#160;<xref rid="psp412737-sup-0017" ref-type="supplementary-material">S2</xref>a,b,d). However, the coefficients in 3 of 18 in <italic toggle="yes">CYP2C19*1</italic>/<italic toggle="yes">*2</italic>IM were higher than 1 (Figure&#160;<xref rid="psp412737-sup-0017" ref-type="supplementary-material">S2</xref>c). The visual comparative figures between <italic toggle="yes">CYP2C19</italic>EM (wild&#8208;type) and <italic toggle="yes">CYP2C19</italic>PM are shown in Figure&#160;<xref rid="psp412737-sup-0017" ref-type="supplementary-material">S2</xref>e. For quinine (DDI model), only 2 of 34&#160;model parameters in Scenario I were higher than 1 (Figure&#160;<xref rid="psp412737-sup-0017" ref-type="supplementary-material">S3</xref>). The sensitivity coefficient over 1 indicates the high sensitivity of quinine clearance in the DDI model to these model parameters.</p></sec><sec id="psp412737-sec-0016"><title>Simulation of standard dose regimen of phenobarbital in patients with seizures with polymorphic <italic toggle="yes">CYP2C19</italic>
</title><sec id="psp412737-sec-0017"><title>Simulation based on standard DDI study approach</title><p>Results of the simulation of potential dose regimens (multiple dosing) of phenobarbital (C<sub>max</sub>, C<sub>min</sub>, and clearance) in patients with wild&#8208;type <italic toggle="yes">CYP2C19</italic>EM and <italic toggle="yes">CYP2C19</italic>IM (<italic toggle="yes">CYP2C19*1/*2</italic> and <italic toggle="yes">CYP2C19*1/*3</italic>) and CYP2C19PM are summarized in Table&#160;<xref rid="psp412737-sup-0002" ref-type="supplementary-material">S2</xref>. Phenobarbital plasma concentrations for individuals with all <italic toggle="yes">CYP2C19</italic>&#160;genotypes are shown in Figure&#160;<xref rid="psp412737-sup-0017" ref-type="supplementary-material">S4</xref>A&#8211;D). The average values of all parameters in all genotypes were within the therapeutic range.</p></sec><sec id="psp412737-sec-0018"><title>Simulation based on actual clinical use only</title><p>Results of the simulation of potential dose regimen (single and multiple dosing) of phenobarbital (C<sub>max</sub>, C<sub>min</sub>, and clearance) in patients with <italic toggle="yes">CYP2C19</italic>EM, <italic toggle="yes">CYP2C19</italic>IM, and <italic toggle="yes">CYP2C19</italic>PM are summarized in Table&#160;<xref rid="psp412737-sup-0003" ref-type="supplementary-material">S3</xref>. Phenobarbital plasma concentrations for all genotypes are shown in Figure&#160;<xref rid="psp412737-sup-0017" ref-type="supplementary-material">S5</xref> and Figure&#160;<xref rid="psp412737-sup-0017" ref-type="supplementary-material">S6</xref> for Scenarios I and II, respectively. The average values in all genotypes were within the therapeutic range.</p></sec></sec><sec id="psp412737-sec-0019"><title>Simulation of the potential dose of quinine when coadministered with phenobarbital in patients with cerebral malaria with concurrent seizures and polymorphic <italic toggle="yes">CYP2C19</italic>
</title><p>Results (C<sub>min</sub>, C<sub>max</sub>, area under the curve ratio [AUCR], and C<sub>max</sub> ratio) of the simulation of the standard dose of quinine when coadministered with phenobarbital in patients with cerebral malaria with concurrent seizures (Scenario I, single seizure; Scenario II, multiple seizures) and polymorphic <italic toggle="yes">CYP2C19</italic> based on the standard DDI and actual clinical use study approaches are summarized in Table&#160;<xref rid="psp412737-sup-0004" ref-type="supplementary-material">S4</xref>.</p><sec id="psp412737-sec-0020"><title>Simulation based on standard DDI study approach</title><p>The standard dose regimen of quinine did not provide optimal plasma drug concentrations when coadministered with phenobarbital (C<sub>min</sub> &lt; 10&#160;mg&#160;L<sup>&#8722;1</sup>; Table&#160;<xref rid="psp412737-sup-0004" ref-type="supplementary-material">S4</xref>). The initial regimen (Regimen 1: a loading dose of 2000&#160;mg i.v. infusion for 4&#160;h followed by maintenance doses of 1000&#160;mg i.v. infusion for 4&#160;h given three times a day) in patients with wild&#8208;type and polymorphic <italic toggle="yes">CYP2C19</italic> provided a twofold increase of quinine concentrations compared with standard quinine regimen. Regimen 1 provided C<sub>max</sub> exceeding 20&#160;mg&#160;L<sup>&#8722;1</sup> but C<sub>min</sub> less than 10&#160;mg&#160;L<sup>&#8722;1</sup> both in wild&#8208;type and polymorphic <italic toggle="yes">CYP2C19</italic> (Figure&#160;<xref rid="psp412737-sup-0017" ref-type="supplementary-material">S7</xref>A and Figure S6B&#8211;D for <italic toggle="yes">CYP2C19</italic>EM, <italic toggle="yes">CYP2C19*1</italic>/<italic toggle="yes">*2</italic>, and <italic toggle="yes">CYP2C19*1</italic>/<italic toggle="yes">*3</italic>, <italic toggle="yes">CYP2C19*2</italic>/<italic toggle="yes">*2</italic>, or <italic toggle="yes">CYP2C19*3</italic>/<italic toggle="yes">*3</italic>, respectively). The time to reach therapeutic concentration ranged from 2 to 3&#160;h. Another subsequent dose regimen was simulated (Regimen 2: a loading dose of 2000&#160;mg i.v. for 8&#160;h followed by maintenance doses of 1200&#160;mg continuous infusion until day 3 [72&#160;h]). Plasma quinine concentration&#8208;time profiles in are shown in Figure&#160;<xref rid="psp412737-fig-0001" ref-type="fig">1</xref>A&#8211;D for the wild&#8208;type CYP2C19EM, <italic toggle="yes">CYP2C19*1</italic>/<italic toggle="yes">*2</italic>IM, and <italic toggle="yes">CYP2C19*1</italic>/<italic toggle="yes">*3</italic> or <italic toggle="yes">CYP2C19</italic>PM, respectively). The time to reach therapeutic concentrations ranged from 4 to 6&#160;h. The pharmacokinetic parameters (C<sub>max</sub>, C<sub>min</sub>, and clearance) for Regimens 1 and 2 are summarized in Table&#160;<xref rid="psp412737-sup-0005" ref-type="supplementary-material">S5</xref>.</p><fig position="float" fig-type="FIGURE" id="psp412737-fig-0001" orientation="portrait"><label>FIGURE 1</label><caption><p>Prediction of quinine dose Regimen 2 in all genotypes based on a standard drug&#8211;drug interaction (DDI) study approach. CYP2C19EM, extensive metabolizer of CYP2C19; CYP2C19PM, poor metabolizer of CYP2C19; CYP2C19IM, intensive metabolizer of CYP2C19</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-1" orientation="portrait" xlink:href="PSP4-11-104-g002.jpg"/></fig></sec><sec id="psp412737-sec-0021"><title>Simulation based on actual clinical use study approach</title><p>The standard dose regimen of quinine provided inappropriate plasma concentrations when coadministered with phenobarbital (C<sub>min</sub> &lt; 10&#160;mg&#160;L<sup>&#8722;1</sup>; Table&#160;<xref rid="psp412737-sup-0004" ref-type="supplementary-material">S4</xref>). The twofold increase of quinine standard dose regimen (based on AUCR; Regimen 1: a loading dose of 2000&#160;mg i.v. infusion for 4&#160;h followed by 1000&#160;mg i.v. for 4&#160;h given three times a day) provided C<sub>max</sub> exceeding 20&#160;mg&#160;L<sup>&#8722;1</sup> and C<sub>min</sub> less than 10&#160;mg&#160;L<sup>&#8722;1</sup> in all genotypes in both scenarios. Plasma quinine concentration&#8208;time profiles in Scenarios I and II in the wild&#8208;type <italic toggle="yes">CYP2C19</italic>EM, <italic toggle="yes">CYP2C19*1</italic>/<italic toggle="yes">*2</italic>IM, and CYP2C19PM are shown in Figure&#160;<xref rid="psp412737-sup-0017" ref-type="supplementary-material">S8</xref> and Figure&#160;<xref rid="psp412737-sup-0017" ref-type="supplementary-material">S9</xref>, respectively. Another subsequent dose regimen for Scenario I (single seizure) and Scenario II (multiple seizures) were simulated (Regimen 2: a loading dose of 2000&#160;mg i.v. infusion for 8&#160;h followed by 1200&#160;mg i.v. continuous infusion until day 3 [72&#160;h]). Plasma quinine concentration&#8208;time profiles for wild&#8208;type and polymorphic <italic toggle="yes">CYP2C19</italic> in Scenarios I and II are presented in Figure&#160;<xref rid="psp412737-fig-0002" ref-type="fig">2</xref> and Figure&#160;<xref rid="psp412737-fig-0003" ref-type="fig">3</xref>, respectively. The pharmacokinetic parameters (C<sub>max</sub>, C<sub>min</sub>, and clearance) for Regimens 1 and 2 are summarized in Tables&#160;<xref rid="psp412737-tbl-0001" ref-type="table">1</xref> and <xref rid="psp412737-tbl-0002" ref-type="table">2</xref>, respectively. Time to reach therapeutic quinine levels ranged from 4 to 6&#160;h.</p><fig position="float" fig-type="FIGURE" id="psp412737-fig-0002" orientation="portrait"><label>FIGURE 2</label><caption><p>Prediction of quinine dose regimens in polymorphic CYP2C19 based on actual clinical use approach (Regimen 2; Scenario I). CYP2C19EM, extensive metabolizer of CYP2C19; CYP2C19PM, poor metabolizer of CYP2C19; CYP2C19IM, intensive metabolizer of CYP2C19)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-3" orientation="portrait" xlink:href="PSP4-11-104-g005.jpg"/></fig><fig position="float" fig-type="FIGURE" id="psp412737-fig-0003" orientation="portrait"><label>FIGURE 3</label><caption><p>Prediction of quinine dose regimens in polymorphic CYP2C19 based on actual clinical use approach (Regimen 2; Scenario II). CYP2C19EM, extensive metabolizer of CYP2C19; CYP2C19PM, poor metabolizer of CYP2C19; CYP2C19IM, intensive metabolizer of CYP2C19</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-5" orientation="portrait" xlink:href="PSP4-11-104-g003.jpg"/></fig><table-wrap position="float" id="psp412737-tbl-0001" content-type="TABLE" orientation="portrait"><label>TABLE 1</label><caption><p>Prediction of quinine dose regimens when coadministered with phenobarbital based on Scenario I</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">Regimen</th><th align="left" valign="top" rowspan="1" colspan="1">C<sub>max</sub> (mg&#160;L<sup>&#8722;1</sup>)</th><th align="left" valign="top" rowspan="1" colspan="1">C<sub>min</sub> (mg&#160;L<sup>&#8722;1</sup>)</th><th align="left" valign="top" rowspan="1" colspan="1">Clearance (L&#160;h<sup>&#8722;1</sup>)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">CYP2C19EM (<italic toggle="yes">CYP2C19*1/*1</italic>)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Regimen 1 (loading dose of 2000&#160;mg i.v. infusion for 4&#160;h followed by 1000&#160;mg i.v. infusion for 4&#160;h [given every 8&#160;h daily])</td><td align="char" char=" " rowspan="1" colspan="1">23.92 &#177; 3.32</td><td align="char" char=" " rowspan="1" colspan="1">9.13 &#177; 3.65</td><td align="char" char=" " rowspan="1" colspan="1">9.61 &#177; 2.82</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Regimen 2 (loading dose of 2000&#160;mg i.v. infusion for 8&#160;h followed by 1200&#160;mg i.v. infusion [given every 8&#160;h daily])</td><td align="char" char=" " rowspan="1" colspan="1">17.33 &#177; 2.99</td><td align="char" char=" " rowspan="1" colspan="1">15.07 &#177; 3.92</td><td align="char" char=" " rowspan="1" colspan="1">10.19 &#177; 2.78</td></tr><tr><td align="left" rowspan="1" colspan="1">CYP2C19IM <italic toggle="yes">(CYP2C19*1/*2)</italic>
</td><td align="char" char="." rowspan="1" colspan="1"/><td align="char" char="." rowspan="1" colspan="1"/><td align="char" char="." rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Regimen 1 (loading dose of 2000&#160;mg i.v. infusion for 4&#160;h followed by 1000&#160;mg i.v. infusion for 4&#160;h [given every 8&#160;h daily])</td><td align="char" char=" " rowspan="1" colspan="1">23.48 &#177; 3.97</td><td align="char" char=" " rowspan="1" colspan="1">8.97 &#177; 3.02</td><td align="char" char=" " rowspan="1" colspan="1">10.41 &#177; 3.17</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Regimen 2 (loading dose of 2000&#160;mg i.v. infusion for 8&#160;h followed by 1200&#160;mg i.v. infusion [given every 8&#160;h daily])</td><td align="char" char=" " rowspan="1" colspan="1">17.33 &#177; 3.58</td><td align="char" char=" " rowspan="1" colspan="1">14.23 &#177; 4.15</td><td align="char" char=" " rowspan="1" colspan="1">10.36 &#177; 3.11</td></tr><tr><td align="left" rowspan="1" colspan="1">CYP2C19PM (<italic toggle="yes">CYP2C19*1/*3</italic>)</td><td align="char" char="." rowspan="1" colspan="1"/><td align="char" char="." rowspan="1" colspan="1"/><td align="char" char="." rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Regimen 1 (loading dose of 2000&#160;mg i.v. infusion for 4&#160;h followed by 1000&#160;mg i.v. infusion for 4&#160;h [given every 8&#160;h daily])</td><td align="char" char=" " rowspan="1" colspan="1">23.32 &#177; 3.33</td><td align="char" char=" " rowspan="1" colspan="1">9.03 &#177; 3.38</td><td align="char" char=" " rowspan="1" colspan="1">10.18 &#177; 3.03</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Regimen 2 (loading dose of 2000&#160;mg i.v. infusion for 8&#160;h followed by 1200&#160;mg i.v. infusion [given every 8&#160;h daily])</td><td align="char" char=" " rowspan="1" colspan="1">17.18 &#177; 3.26</td><td align="char" char=" " rowspan="1" colspan="1">14.34 &#177; 4.21</td><td align="char" char=" " rowspan="1" colspan="1">10.40 &#177; 3.24</td></tr><tr><td align="left" rowspan="1" colspan="1">CYP2C19EM (<italic toggle="yes">CYP2C19*2/*2</italic> or <italic toggle="yes">CYP2C19*3/*3</italic>)</td><td align="char" char="." rowspan="1" colspan="1"/><td align="char" char="." rowspan="1" colspan="1"/><td align="char" char="." rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Regimen 1 (loading dose of 2000&#160;mg i.v. infusion for 4&#160;h followed by 1000&#160;mg i.v. infusion for 4&#160;h [given every 8&#160;h daily])</td><td align="char" char=" " rowspan="1" colspan="1">23.50 &#177; 3.32</td><td align="char" char=" " rowspan="1" colspan="1">8.97 &#177; 3.66</td><td align="char" char=" " rowspan="1" colspan="1">10.05 &#177; 3.21</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Regimen 2 (loading dose of 2000&#160;mg i.v. infusion or 8&#160;h followed by 1200&#160;mg i.v. infusion [given every 8&#160;h daily])</td><td align="char" char=" " rowspan="1" colspan="1">17.59 &#177; 2.49</td><td align="char" char=" " rowspan="1" colspan="1">14.37 &#177; 4.12</td><td align="char" char=" " rowspan="1" colspan="1">9.71 &#177; 2.25</td></tr></tbody></table><table-wrap-foot id="psp412737-ntgp-0002"><title>Note</title><fn id="psp412737-note-0002"><p>Data are presented as mean &#177; SD.</p></fn><fn id="psp412737-note-0003"><p>Abbreviations: CYP2C19EM, extensive metabolizer of CYP2C19; CYP2C19PM, poor metabolizer of CYP2C19; CYP2C19IM, intensive metabolizer of CYP2C19; C<sub>max</sub>, peak plasma concentration; C<sub>min</sub>, minimal plasma concentration; EM, extensive metabolizer; i.v., intravenous; PM, poor metabolizer.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder></permissions></table-wrap><table-wrap position="float" id="psp412737-tbl-0002" content-type="TABLE" orientation="portrait"><label>TABLE 2</label><caption><p>Prediction of quinine dose regimens when coadministered with phenobarbital based on Scenario II</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">Regimen</th><th align="left" valign="top" rowspan="1" colspan="1">C<sub>max</sub> (mg&#160;L<sup>&#8722;1</sup>)</th><th align="left" valign="top" rowspan="1" colspan="1">C<sub>min</sub> (mg&#160;L<sup>&#8722;1</sup>)</th><th align="left" valign="top" rowspan="1" colspan="1">Clearance (L&#160;h<sup>&#8722;1</sup>)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">CYP2C19EM (<italic toggle="yes">CYP2C19*1/*1</italic>)</td><td align="char" char="." rowspan="1" colspan="1"/><td align="char" char="." rowspan="1" colspan="1"/><td align="char" char="." rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Regimen 1 (loading dose of 2000&#160;mg i.v. infusion for 4&#160;h followed by 1000&#160;mg i.v. infusion for 4&#160;h [given every 8&#160;h daily])</td><td align="char" char=" " rowspan="1" colspan="1">23.73 &#177; 3.12</td><td align="char" char=" " rowspan="1" colspan="1">8.1 &#177; 3.29</td><td align="char" char=" " rowspan="1" colspan="1">9.94 &#177; 2.72</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Regimen 2 (loading dose of 2000&#160;mg i.v. infusion for 8&#160;h followed by 1200&#160;mg i.v. infusion [given every 8&#160;h daily])</td><td align="char" char=" " rowspan="1" colspan="1">17.87 &#177; 3.59</td><td align="char" char=" " rowspan="1" colspan="1">14.00 &#177; 4.45</td><td align="char" char=" " rowspan="1" colspan="1">9.99 &#177; 2.69</td></tr><tr><td align="left" rowspan="1" colspan="1">CYP2C19IM (<italic toggle="yes">CYP2C19*1/*2</italic>)</td><td align="char" char="." rowspan="1" colspan="1"/><td align="char" char="." rowspan="1" colspan="1"/><td align="char" char="." rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Regimen 1 (loading dose of 2000&#160;mg i.v. infusion for 4&#160;h followed by 1000&#160;mg i.v. infusion for 4&#160;h [given every 8&#160;h daily])</td><td align="char" char=" " rowspan="1" colspan="1">23.46 &#177; 3.18</td><td align="char" char=" " rowspan="1" colspan="1">8.40 &#177; 2.87</td><td align="char" char=" " rowspan="1" colspan="1">10.17 &#177; 2.83</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Regimen 2 (loading dose of 2000&#160;mg i.v. infusion for 8&#160;h followed by 1200&#160;mg i.v. infusion [given every 8&#160;h daily])</td><td align="char" char=" " rowspan="1" colspan="1">17.42 &#177; 3.65</td><td align="char" char=" " rowspan="1" colspan="1">14.01 &#177; 4.94</td><td align="char" char=" " rowspan="1" colspan="1">10.53 &#177; 3.30</td></tr><tr><td align="left" rowspan="1" colspan="1">CYP2C19PM (<italic toggle="yes">CYP2C19*1/*3</italic>)</td><td align="char" char="." rowspan="1" colspan="1"/><td align="char" char="." rowspan="1" colspan="1"/><td align="char" char="." rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Regimen 1 (loading dose of 2000&#160;mg i.v. infusion for 4&#160;h followed by 1000&#160;mg i.v. infusion for 4&#160;h [given every 8&#160;h daily])</td><td align="char" char=" " rowspan="1" colspan="1">23.38 &#177; 3.26</td><td align="char" char=" " rowspan="1" colspan="1">8.23 &#177; 3.01</td><td align="char" char=" " rowspan="1" colspan="1">10.56 &#177; 3.09</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Regimen 2 (loading dose of 2000&#160;mg i.v. infusion for 8&#160;h followed by 1200&#160;mg i.v. infusion [given every 8&#160;h daily])</td><td align="char" char=" " rowspan="1" colspan="1">17.67 &#177; 3.37</td><td align="char" char=" " rowspan="1" colspan="1">13.64 &#177; 3.93</td><td align="char" char=" " rowspan="1" colspan="1">10.28 &#177; 3.09</td></tr><tr><td align="left" rowspan="1" colspan="1">CYP2C19EM (<italic toggle="yes">CYP2C19*2/*2</italic> or <italic toggle="yes">CYP2C19*3/*3</italic>)</td><td align="char" char="." rowspan="1" colspan="1"/><td align="char" char="." rowspan="1" colspan="1"/><td align="char" char="." rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Regimen 1 (loading dose of 2000&#160;mg i.v. infusion for 4&#160;h followed by 1000&#160;mg i.v. infusion for 4&#160;h [given every 8&#160;h daily])</td><td align="char" char=" " rowspan="1" colspan="1">23.38 &#177; 3.17</td><td align="char" char=" " rowspan="1" colspan="1">8.25 &#177; 3.16</td><td align="char" char=" " rowspan="1" colspan="1">10.47 &#177; 3.00</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Regimen 2 (loading dose of 2000&#160;mg i.v. infusion for 8&#160;h followed by 1200&#160;mg i.v. infusion [given every 8&#160;h daily])</td><td align="char" char=" " rowspan="1" colspan="1">17.37 &#177; 2.88</td><td align="char" char=" " rowspan="1" colspan="1">13.68 &#177; 3.94</td><td align="char" char=" " rowspan="1" colspan="1">10.34 &#177; 2.82</td></tr></tbody></table><table-wrap-foot id="psp412737-ntgp-0003"><title>Note</title><fn id="psp412737-note-0004"><p>Data are presented as mean &#177; SD.</p></fn><fn id="psp412737-note-0005"><p>Abbreviations: CYP2C19EM, extensive metabolizer of CYP2C19; CYP2C19PM, poor metabolizer of CYP2C19; CYP2C19IM, intensive metabolizer of CYP2C19; C<sub>max</sub>, peak plasma concentration; C<sub>min</sub>, minimal plasma concentration; EM, extensive metabolizer; i.v., intravenous; PM, poor metabolizer.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder></permissions></table-wrap></sec></sec><sec id="psp412737-sec-0022"><title>Simulation of the potential dose of quinine when coadministered with phenobarbital in patients with cerebral malaria with concurrent seizures and acute renal failure with lactic acidosis</title><sec id="psp412737-sec-0023"><title>Simulation based on actual clinical use study approach</title><p>The potential quinine dosage regimen (Regimen 2) when coadministered with phenobarbital in patients with different degrees of eGFR from Scenarios I and II was simulated. Plasma concentration&#8211;time profiles of quinine in patients in all groups were within the therapeutic range (Figure&#160;<xref rid="psp412737-fig-0004" ref-type="fig">4</xref> and Figure&#160;<xref rid="psp412737-fig-0005" ref-type="fig">5</xref> for Scenarios I and II, respectively). Therefore, no further subsequent dose regimens were simulated.</p><fig position="float" fig-type="FIGURE" id="psp412737-fig-0004" orientation="portrait"><label>FIGURE 4</label><caption><p>Prediction of quinine dose regimens based on actual clinical use approach (Scenario I) in patients with cerebral malaria with concurrent seizures and acute renal failure (corrected with lactic acidosis) who carry polymorphic CYP2C19EM (Regimen 2). CYP2C19EM, extensive metabolizer of CYP2C19; CYP2C19PM, poor metabolizer of CYP2C19; CYP2C19IM, intensive metabolizer of CYP2C19; eGFR, estimated glomerular filtration rate; RIFLE&#8208;F, risk, injury, failure, loss of kidney function and end&#8208;stage kidney disease&#8211;failure; RIFLE&#8208;I, risk, injury, failure, loss of kidney function and end&#8208;stage kidney disease&#8211;injury; RIFLE&#8208;R, risk, injury, failure, loss of kidney function and end&#8208;stage kidney disease&#8211;risk</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-7" orientation="portrait" xlink:href="PSP4-11-104-g001.jpg"/></fig><fig position="float" fig-type="FIGURE" id="psp412737-fig-0005" orientation="portrait"><label>FIGURE 5</label><caption><p>Prediction of quinine dose regimens based on actual clinical use approach (Scenario II) in patients with cerebral malaria with concurrent seizures and acute renal failure (corrected with lactic acidosis) who carry polymorphic CYP2C19EM and CYP2C19PM. CYP2C19EM, extensive metabolizer of CYP2C19; CYP2C19PM, poor metabolizer of CYP2C19; CYP2C19IM, intensive metabolizer of CYP2C19; eGFR, estimated glomerular filtration rate; RIFLE&#8208;F, risk, injury, failure, loss of kidney function and end&#8208;stage kidney disease&#8211;failure; RIFLE&#8208;I, risk, injury, failure, loss of kidney function and end&#8208;stage kidney disease&#8211;injury; RIFLE&#8208;R, risk, injury, failure, loss of kidney function and end&#8208;stage kidney disease&#8211;risk</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-9" orientation="portrait" xlink:href="PSP4-11-104-g004.jpg"/></fig></sec></sec></sec><sec sec-type="discussion" id="psp412737-sec-0024"><title>DISCUSSION</title><p>The current study successfully developed the DDI PBPK models. Although the sensitivity coefficients of some parameters were greater than 1, these parameters were obtained from experimental studies with low variability. The DDI PBPK models are therefore credible. Results of this study based on PBPK modeling and simulation raise a concern about the potential DDIs between quinine and phenobarbital when were coadministered in patients with cerebral malaria with concurrent seizures. The conventional dose adjustment based on the AUCR of both drugs in different clinical scenarios may provide suboptimal dose regimens with inadequate trough plasma levels, which will pose the patients at risk of treatment failure and/or severe complications. The PBPK modeling approach, on the other hand, has proved a promising tool for dose optimization of quinine and phenobarbital coadministration.</p><sec id="psp412737-sec-0025"><title>Potential phenobarbital dose regimens in patients with seizures with polymorphic <italic toggle="yes">CYP2C19</italic>
</title><p>Simulation of the optimal phenobarbital dose regimens in patients with seizures who carry polymorphic <italic toggle="yes">CYP2C19</italic> was investigated using dose regimens based on the two approaches, that is, the standard DDI study approach (at steady state of phenobarbital level) and the actual clinical use study approach (Scenario I for single seizure and Scenario II for continuous seizures). Results supported the previous report of the decrease in total clearance of phenobarbital by 1% and 21% and 27% in patients carrying the <italic toggle="yes">CYP2C19</italic>*1/*2IM, <italic toggle="yes">CYP2C19*1</italic>/<italic toggle="yes">*3</italic>PM, and <italic toggle="yes">CYP2C19</italic>PM (<italic toggle="yes">*2</italic>/<italic toggle="yes">*2</italic> or <italic toggle="yes">*3</italic>/<italic toggle="yes">*3</italic>) genotypes, respectively.<xref rid="psp412737-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref>&#160;The reported frequencies of the wild&#8208;type, <italic toggle="yes">CYP2C19</italic>EM, and <italic toggle="yes">CYP2C19</italic>PM genotypes in the Thai population are 42%,<xref rid="psp412737-bib-0045" ref-type="bibr">
<sup>45</sup>
</xref> 2.8%,<xref rid="psp412737-bib-0046" ref-type="bibr">
<sup>46</sup>
</xref> and 13%,<xref rid="psp412737-bib-0045" ref-type="bibr">
<sup>45</sup>
</xref> respectively. Based on the results of PBPK modeling using both the DDI and actual clinical use study approaches, however, dosage adjustment of phenobarbital may not be required as plasma drug concentrations were maintained within the therapeutic range, that is, C<sub>max</sub> &#8804; 40&#160;mg&#160;L<sup>&#8722;1</sup>
<xref rid="psp412737-bib-0044" ref-type="bibr">
<sup>44</sup>
</xref> and C<sub>min</sub>&#8805; 15&#160;mg&#160;L<sup>&#8722;1</sup>.<xref rid="psp412737-bib-0044" ref-type="bibr">
<sup>44</sup>
</xref>&#160;The proposed phenobarbital dosage regimens are optimal for the treatment of patients with single seizure (single dose of 900&#160;mg or 15&#160;mg&#160;kg<sup>&#8722;1</sup>) as well as patients with cerebral malaria who have continuous seizures (a loading dose of 15&#160;mg&#160;kg<sup>&#8722;1&#160;</sup>day<sup>&#8722;1</sup> followed by 1.5&#160;mg&#160;kg<sup>&#8722;1</sup>&#160;day<sup>&#8722;1</sup> once daily) regardless of patients&#8217; <italic toggle="yes">CYP2C19</italic>&#160;genotypes. Genotyping is therefore not necessary, which is practical both in developed and developing countries. Also, the advantage of using phenobarbital over other anticonvulsants is its relatively low cost.<xref rid="psp412737-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref>
</p></sec><sec id="psp412737-sec-0026"><title>Potential quinine dose regimens when coadministered with phenobarbital in patients with cerebral malaria with concurrent seizures and polymorphic <italic toggle="yes">CYP2C19</italic>
</title><p>Similarly to phenobarbital, simulation of the potential quinine dose regimens in patients with concurrent cerebral malaria and seizures with polymorphic <italic toggle="yes">CYP2C19</italic> were investigated using dose regimens based on the standard DDI study and actual clinical use (Scenarios I and II) study approaches. Dose optimization based on AUCR yielded undesirable plasma quinine concentrations when coadministered with phenobarbital. The recommended quinine dosage regimen obtained from the standard DDI approach or actual clinical study use approach was similar. Therefore, the standard DDI approach used could be satisfactorily applied in the real clinical scenarios.</p><sec id="psp412737-sec-0027"><title>Simulation based on standard approach</title><p>The proposed quinine dosage Regimen 2 provided adequate C<sub>min</sub> above 10&#160;mg&#160;L<sup>&#8722;1</sup> and C<sub>max</sub> under 20&#160;mg&#160;L<sup>&#8722;1</sup> in wild&#8208;type genotype and polymorphic <italic toggle="yes">CYP2C19</italic> (Figure&#160;<xref rid="psp412737-fig-0001" ref-type="fig">1</xref>A&#8211;D). Therefore, this regimen was considered as the recommended dosage regimen of quinine when coadministered with phenobarbital because it provided plasma quinine concentrations within the therapeutic range. It is noted, however, that the infusion duration of 8&#160;h (continuous infusion) might result in the delay of time to reach therapeutic level compared with the recommended standard regimen (4&#8211;6 and 2&#8211;3&#160;h for the potentially recommended and standard regimen, respectively). Because the critical period for treatment of patients with cerebral malaria is during the first 24&#160;h,<xref rid="psp412737-bib-0031" ref-type="bibr">
<sup>31</sup>
</xref>&#160;such a delay is unlikely to pose the patients at risk of complicated manifestation or death.</p></sec><sec id="psp412737-sec-0028"><title>Simulation based on actual clinical use study approach</title><p>Optimal C<sub>max</sub> and C<sub>min</sub> of quinine were achieved with adequate plasma concentrations following the proposed quinine dose regimen (Regimen 2) when coadministered with phenobarbital in both clinical scenarios (Scenario I for single seizure and Scenario II for continuous seizures) using PBPK modeling and simulation, but not the AUCR, (Figure&#160;<xref rid="psp412737-fig-0002" ref-type="fig">2</xref>A&#8211;D for Scenario I and Figure&#160;<xref rid="psp412737-fig-0003" ref-type="fig">3</xref>A&#8211;D for Scenario II). This quinine regimen can be coadministered with phenobarbital without consideration of <italic toggle="yes">CYP2C19</italic>&#160;genotypes because plasma quinine concentrations in patients with wild&#8208;type and polymorphic <italic toggle="yes">CYP2C19</italic> were comparable. There is no influence of <italic toggle="yes">CYP2C19</italic>&#160;genotypes on the inducing effect of quinine metabolism because the steady&#8208;state drug concentrations are not achieved with a short duration of phenobarbital dosing. It is noted that the recommended dose regimens of quinine and phenobarbital coadministration apply to patients with cerebral malaria with seizures who have normal hepatic function but not in those with impaired function. Therapeutic drug monitoring for quinine in those patients is recommended.</p></sec></sec><sec id="psp412737-sec-0029"><title>Simulation of the potential dose of quinine when coadministered with phenobarbital in patients with cerebral malaria with concurrent seizures and acute renal failure with lactic acidosis</title><sec id="psp412737-sec-0030"><title>Simulation based on actual clinical use study approach</title><p>The recommended quinine dosage regimen in patients with cerebral malaria with seizure without acute renal failure and lactic acidosis can be applied to patients who have acute renal failure and lactic acidosis because plasma quinine concentrations were within the therapeutic range (Figure&#160;<xref rid="psp412737-fig-0004" ref-type="fig">4</xref> and Figure&#160;<xref rid="psp412737-fig-0005" ref-type="fig">5</xref> for Scenarios I and II, respectively). Thus, no dosage adjustment was needed. It was noted for the absence of influence of the state of acute renal failure (decrease of eGFR) on plasma quinine concentrations due to low renal excretion of quinine and phenobarbital.</p><p>The limitations of the study include the exclusion of the contribution of P&#8208;glycoprotein transporter on quinine disposition (due to lack of information on in vitro studies) as well as the inhibitory effect of 3&#8208;hydroxyquinine metabolite on CYP3A4 activity. Nevertheless, the significant impacts of these two factors on quinine disposition are unlikely.<xref rid="psp412737-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref> Because of the limited information on phenobarbital i.v. infusion in patients, one publication in healthy volunteers was used for phenobarbital model validation. Relying on the data only from one publication may be insufficient for model validation. Malaria infection may change the pharmacokinetics of phenobarbital through alteration of f<sub>u</sub>, although there is no evidence to support such supposition. In addition, most sensitivity coefficients of the model parameters used for construction of the phenobarbital PBPK models were lower than 1, indicating the insensitivity of the model to the changing of parameters.</p><p>In conclusion, PBPK modeling is a promising tool for dose optimization of quinine in patients with cerebral malaria in resource&#8208;limited countries. The developed PBPK models for phenobarbital and quinine&#8211;phenobarbital coadministration are reliable. They successfully predicted the optimal doses regimens of phenobarbital in patients with cerebral malaria with single or continuous seizures with no requirement of <italic toggle="yes">CYP2C19</italic>&#160;genotyping. Dose adjustment based on PBPK modeling but not AUCR provided desirable plasma quinine concentrations. Dose adjustment of the standard regimen of phenobarbital is not required when coadministered with quinine. The proposed potential dose regimen for quinine when coadministered with phenobarbital for patients with a single seizure (Scenario I) and continuous seizures (Scenario II) in all malaria&#8208;endemic areas regardless of <italic toggle="yes">CYP2C19</italic>&#160;genotypes is a loading dose of 2000&#160;mg i.v. infusion for 8&#160;h followed by 1200&#160;mg i.v. continuous infusion until day 3 (72&#160;h).</p></sec></sec></sec><sec sec-type="COI-statement" id="psp412737-sec-0031"><title>CONFLICT OF INTEREST</title><p>The authors declared no conflict of interest.</p></sec><sec id="psp412737-sec-0032"><title>AUTHOR CONTRIBUTIONS</title><p>T.S., J.K., and K.N. wrote the manuscript. T.S., J.K., M.S., and K.N. designed the research. T.S., R.K.R.R., and M.S. performed research. T.S., R.K.R.R., M.S., and K.N. analyzed the data. T.S., R.K.R.R., and M.S. contributed new reagents/analytical tools.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="psp412737-sup-0001" position="float" content-type="local-data" orientation="portrait"><caption><p>Table S1</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="PSP4-11-104-s008.docx" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material id="psp412737-sup-0002" position="float" content-type="local-data" orientation="portrait"><caption><p>Table S2</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="PSP4-11-104-s014.docx" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material id="psp412737-sup-0003" position="float" content-type="local-data" orientation="portrait"><caption><p>Table S3</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="PSP4-11-104-s015.docx" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material id="psp412737-sup-0004" position="float" content-type="local-data" orientation="portrait"><caption><p>Table S4</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="PSP4-11-104-s012.docx" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material id="psp412737-sup-0005" position="float" content-type="local-data" orientation="portrait"><caption><p>Table S5</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="PSP4-11-104-s017.docx" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material id="psp412737-sup-0006" position="float" content-type="local-data" orientation="portrait"><caption><p>Table S6</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="PSP4-11-104-s006.docx" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material id="psp412737-sup-0007" position="float" content-type="local-data" orientation="portrait"><caption><p>Table S7</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="PSP4-11-104-s011.docx" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material id="psp412737-sup-0008" position="float" content-type="local-data" orientation="portrait"><caption><p>Fig S1</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="PSP4-11-104-s002.docx" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material id="psp412737-sup-0009" position="float" content-type="local-data" orientation="portrait"><caption><p>Fig S2</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="PSP4-11-104-s003.docx" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material id="psp412737-sup-0010" position="float" content-type="local-data" orientation="portrait"><caption><p>Fig S3</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="PSP4-11-104-s010.docx" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material id="psp412737-sup-0011" position="float" content-type="local-data" orientation="portrait"><caption><p>Fig S4</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="PSP4-11-104-s016.docx" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material id="psp412737-sup-0012" position="float" content-type="local-data" orientation="portrait"><caption><p>Fig S5</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="PSP4-11-104-s009.docx" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material id="psp412737-sup-0013" position="float" content-type="local-data" orientation="portrait"><caption><p>Fig S6</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="PSP4-11-104-s007.docx" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material id="psp412737-sup-0014" position="float" content-type="local-data" orientation="portrait"><caption><p>Fig S7</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="PSP4-11-104-s001.docx" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material id="psp412737-sup-0015" position="float" content-type="local-data" orientation="portrait"><caption><p>Fig S8</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="PSP4-11-104-s013.docx" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material id="psp412737-sup-0016" position="float" content-type="local-data" orientation="portrait"><caption><p>Fig S9</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="PSP4-11-104-s004.docx" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material id="psp412737-sup-0017" position="float" content-type="local-data" orientation="portrait"><caption><p>Supplementary Material</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="PSP4-11-104-s005.zip" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ref-list content-type="cited-references" id="psp412737-bibl-0001"><title>REFERENCES</title><ref id="psp412737-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="psp412737-cit-0001"><string-name name-style="western"><surname>Durrani</surname><given-names>AB</given-names></string-name>, <string-name name-style="western"><surname>Durrani</surname><given-names>IU</given-names></string-name>, <string-name name-style="western"><surname>Abbas</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Jabeen</surname><given-names>M</given-names></string-name>. <article-title>Epidemiology of cerebral malaria and its mortality</article-title>. <source>J Pak Med Assoc</source>. <year>1997</year>;<volume>47</volume>(<issue>8</issue>):<fpage>213</fpage>&#8208;<lpage>215</lpage>.<pub-id pub-id-type="pmid">9339620</pub-id></mixed-citation></ref><ref id="psp412737-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="psp412737-cit-0002"><string-name name-style="western"><surname>Idro</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Jenkins</surname><given-names>NE</given-names></string-name>, <string-name name-style="western"><surname>Newton</surname><given-names>CR</given-names></string-name>. <article-title>Pathogenesis, clinical features, and neurological outcome of cerebral malaria</article-title>. <source>Lancet Neurol</source>. <year>2005</year>;<volume>4</volume>(<issue>12</issue>):<fpage>827</fpage>&#8208;<lpage>840</lpage>.<pub-id pub-id-type="pmid">16297841</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1474-4422(05)70247-7</pub-id></mixed-citation></ref><ref id="psp412737-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="psp412737-cit-0003"><string-name name-style="western"><surname>Newton</surname><given-names>CR</given-names></string-name>, <string-name name-style="western"><surname>Hien</surname><given-names>TT</given-names></string-name>, <string-name name-style="western"><surname>White</surname><given-names>N</given-names></string-name>. <article-title>Cerebral malaria</article-title>. <source>J Neurol Neurosurg Psychia</source>. <year>2000</year>;<volume>69</volume>(<issue>4</issue>):<fpage>433</fpage>&#8208;<lpage>441</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jnnp.69.4.433</pub-id><pub-id pub-id-type="pmcid">PMC1737146</pub-id><pub-id pub-id-type="pmid">10990500</pub-id></mixed-citation></ref><ref id="psp412737-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="psp412737-cit-0004"><string-name name-style="western"><surname>Ampadu</surname><given-names>HH</given-names></string-name>, <string-name name-style="western"><surname>Asante</surname><given-names>KP</given-names></string-name>, <string-name name-style="western"><surname>Bosomprah</surname><given-names>S</given-names></string-name>, et al. <article-title>Prescribing patterns and compliance with World Health Organization recommendations for the management of severe malaria: a modified cohort event monitoring study in public health facilities in Ghana and Uganda</article-title>. <source>Malar J</source>. <year>2019</year>;<volume>18</volume>(<issue>1</issue>):<fpage>36</fpage>.<pub-id pub-id-type="pmid">30736864</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12936-019-2670-9</pub-id><pub-id pub-id-type="pmcid">PMC6368732</pub-id></mixed-citation></ref><ref id="psp412737-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="psp412737-cit-0005"><string-name name-style="western"><surname>Chisholm</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Who</surname><given-names>C</given-names></string-name>. <article-title>Cost&#8208;effectiveness of first&#8208;line antiepileptic drug treatments in the developing world: a population&#8208;level analysis</article-title>. <source>Epilepsia</source>. <year>2005</year>;<volume>46</volume>(<issue>5</issue>):<fpage>751</fpage>&#8208;<lpage>759</lpage>.<pub-id pub-id-type="pmid">15857443</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1528-1167.2005.52704.x</pub-id></mixed-citation></ref><ref id="psp412737-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="psp412737-cit-0006"><string-name name-style="western"><surname>Meremikwu</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Marson</surname><given-names>AG</given-names></string-name>. <article-title>Routine anticonvulsants for treating cerebral malaria</article-title>. <source>Cochrane Database Syst Rev</source>. <year>2000</year>;<volume>2</volume>(<issue>2</issue>):<fpage>CD002152</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/14651858.CD002152</pub-id><pub-id pub-id-type="pmcid">PMC6532751</pub-id><pub-id pub-id-type="pmid">12076440</pub-id></mixed-citation></ref><ref id="psp412737-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="psp412737-cit-0007"><string-name name-style="western"><surname>Manuyakorn</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Siripool</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Kamchaisatian</surname><given-names>W</given-names></string-name>, et al. <article-title>Phenobarbital&#8208;induced severe cutaneous adverse drug reactions are associated with CYP2C19*2 in Thai children</article-title>. <source>Pediatr Allergy Immunol</source>. <year>2013</year>;<volume>24</volume>(<issue>3</issue>):<fpage>299</fpage>&#8208;<lpage>303</lpage>.<pub-id pub-id-type="pmid">23551241</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/pai.12058</pub-id></mixed-citation></ref><ref id="psp412737-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="psp412737-cit-0008"><string-name name-style="western"><surname>Mamiya</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Hadama</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Yukawa</surname><given-names>E</given-names></string-name>, et al. <article-title>CYP2C19 polymorphism effect on phenobarbitone. Pharmacokinetics in Japanese patients with epilepsy: analysis by population pharmacokinetics</article-title>. <source>Eur J Clin Pharmacol</source>. <year>2000</year>;<volume>55</volume>(<issue>11&#8211;12</issue>):<fpage>821</fpage>&#8208;<lpage>825</lpage>.<pub-id pub-id-type="pmid">10805060</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s002280050703</pub-id></mixed-citation></ref><ref id="psp412737-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="psp412737-cit-0009"><string-name name-style="western"><surname>Yukawa</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Mamiya</surname><given-names>K</given-names></string-name>. <article-title>Effect of CYP2C19 genetic polymorphism on pharmacokinetics of phenytoin and phenobarbital in Japanese epileptic patients using Non&#8208;linear Mixed Effects Model approach</article-title>. <source>J Clin Pharm Ther</source>. <year>2006</year>;<volume>31</volume>(<issue>3</issue>):<fpage>275</fpage>&#8208;<lpage>282</lpage>.<pub-id pub-id-type="pmid">16789993</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2710.2006.00712.x</pub-id></mixed-citation></ref><ref id="psp412737-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="psp412737-cit-0010"><string-name name-style="western"><surname>Mirghani</surname><given-names>RA</given-names></string-name>, <string-name name-style="western"><surname>Hellgren</surname><given-names>U</given-names></string-name>, <string-name name-style="western"><surname>Bertilsson</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Gustafsson</surname><given-names>LL</given-names></string-name>, <string-name name-style="western"><surname>Ericsson</surname><given-names>O</given-names></string-name>. <article-title>Metabolism and elimination of quinine in healthy volunteers</article-title>. <source>Eur J Clin Pharmacol</source>. <year>2003</year>;<volume>59</volume>(<issue>5&#8211;6</issue>):<fpage>423</fpage>&#8208;<lpage>427</lpage>.<pub-id pub-id-type="pmid">12920491</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00228-003-0637-8</pub-id></mixed-citation></ref><ref id="psp412737-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="psp412737-cit-0011"><string-name name-style="western"><surname>Ramirez</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Komoroski</surname><given-names>BJ</given-names></string-name>, <string-name name-style="western"><surname>Mirkov</surname><given-names>S</given-names></string-name>, et al. <article-title>Study of the genetic determinants of UGT1A1 inducibility by phenobarbital in cultured human hepatocytes</article-title>. <source>Pharmacogenet Genom</source>. <year>2006</year>;<volume>16</volume>(<issue>2</issue>):<fpage>79</fpage>&#8208;<lpage>86</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/01.fpc.0000182784.77630.48</pub-id><pub-id pub-id-type="pmid">16424820</pub-id></mixed-citation></ref><ref id="psp412737-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="psp412737-cit-0012"><string-name name-style="western"><surname>Almond</surname><given-names>LM</given-names></string-name>, <string-name name-style="western"><surname>Mukadam</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Gardner</surname><given-names>I</given-names></string-name>, et al. <article-title>Prediction of drug&#8208;drug interactions arising from CYP3A induction using a physiologically based dynamic model</article-title>. <source>Drug Metab Dispos</source>. <year>2016</year>;<volume>44</volume>(<issue>6</issue>):<fpage>821</fpage>&#8208;<lpage>832</lpage>.<pub-id pub-id-type="pmid">27026679</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/dmd.115.066845</pub-id><pub-id pub-id-type="pmcid">PMC4885489</pub-id></mixed-citation></ref><ref id="psp412737-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="psp412737-cit-0013"><string-name name-style="western"><surname>Brodie</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>Mintzer</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Pack</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Gidal</surname><given-names>BE</given-names></string-name>, <string-name name-style="western"><surname>Vecht</surname><given-names>CJ</given-names></string-name>, <string-name name-style="western"><surname>Schmidt</surname><given-names>D</given-names></string-name>. <article-title>Enzyme induction with antiepileptic drugs: cause for concern?</article-title><source>Epilepsia</source>. <year>2012</year>;<volume>54</volume>(<issue>1</issue>):<fpage>11</fpage>&#8208;<lpage>27</lpage>.<pub-id pub-id-type="pmid">23016553</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1528-1167.2012.03671.x</pub-id></mixed-citation></ref><ref id="psp412737-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="psp412737-cit-0014"><string-name name-style="western"><surname>Plummer</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Beaumont</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Elcombe</surname><given-names>M</given-names></string-name>, et al. <article-title>Species differences in phenobarbital&#8208;mediated UGT gene induction in rat and human liver microtissues</article-title>. <source>Toxicol Rep</source>. <year>2020</year>;<volume>29</volume>(<issue>8</issue>):<fpage>155</fpage>&#8208;<lpage>161</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.toxrep.2020.12.019</pub-id><pub-id pub-id-type="pmcid">PMC7803626</pub-id><pub-id pub-id-type="pmid">33473352</pub-id></mixed-citation></ref><ref id="psp412737-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="psp412737-cit-0015"><string-name name-style="western"><surname>Verdier</surname><given-names>MC</given-names></string-name>, <string-name name-style="western"><surname>Bentue&#8208;Ferrer</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Tribut</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Therap</surname><given-names>SFP</given-names></string-name>. <article-title>Therapeutic drug monitoring of quinine</article-title>. <source>Therapie</source>. <year>2011</year>;<volume>66</volume>(<issue>6</issue>):<fpage>507</fpage>&#8208;<lpage>516</lpage>.<pub-id pub-id-type="pmid">22186076</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2515/therapie/2011071</pub-id></mixed-citation></ref><ref id="psp412737-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="psp412737-cit-0016"><string-name name-style="western"><surname>Boushab</surname><given-names>BM</given-names></string-name>, <string-name name-style="western"><surname>Salem</surname><given-names>MSOA</given-names></string-name>, <string-name name-style="western"><surname>Boukhary</surname><given-names>AOMS</given-names></string-name>, <string-name name-style="western"><surname>Parola</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Basco</surname><given-names>L</given-names></string-name>. <article-title>Clinical features and mortality associated with severe malaria in adults in southern Mauritania</article-title>. <source>Trop Med Infect Dis</source>. <year>2021</year>;<volume>6</volume>(<issue>1</issue>):<fpage>1</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/tropicalmed6010001</pub-id><pub-id pub-id-type="pmcid">PMC7838900</pub-id><pub-id pub-id-type="pmid">33375214</pub-id></mixed-citation></ref><ref id="psp412737-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="psp412737-cit-0017"><string-name name-style="western"><surname>Shebley</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Sandhu</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Emami Riedmaier</surname><given-names>A</given-names></string-name>, et al. <article-title>Physiologically based pharmacokinetic model qualification and reporting procedures for regulatory submissions: a consortium perspective</article-title>. <source>Clin Pharmacol Ther</source>. <year>2018</year>;<volume>104</volume>(<issue>1</issue>):<fpage>88</fpage>&#8208;<lpage>110</lpage>.<pub-id pub-id-type="pmid">29315504</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cpt.1013</pub-id><pub-id pub-id-type="pmcid">PMC6032820</pub-id></mixed-citation></ref><ref id="psp412737-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="psp412737-cit-0018"><string-name name-style="western"><surname>Saeheng</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Na&#8208;Bangchang</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Siccardi</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Rajoli</surname><given-names>RKR</given-names></string-name>, <string-name name-style="western"><surname>Karbwang</surname><given-names>J</given-names></string-name>. <article-title>Physiologically&#8208;based pharmacokinetic modeling for optimal dosage prediction of quinine coadministered with ritonavir&#8208;boosted lopinavir</article-title>. <source>Clin Pharmacol Ther</source>. <year>2019</year>;<volume>107</volume>(<issue>5</issue>):<fpage>1209</fpage>&#8208;<lpage>1220</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cpt.1721</pub-id><pub-id pub-id-type="pmid">31721171</pub-id></mixed-citation></ref><ref id="psp412737-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="psp412737-cit-0019"><string-name name-style="western"><surname>Rajoli</surname><given-names>RK</given-names></string-name>, <string-name name-style="western"><surname>Back</surname><given-names>DJ</given-names></string-name>, <string-name name-style="western"><surname>Rannard</surname><given-names>S</given-names></string-name>, et al. <article-title>Physiologically based pharmacokinetic modelling to inform development of intramuscular long&#8208;acting nanoformulations for HIV</article-title>. <source>Clin Pharmacokinet</source>. <year>2015</year>;<volume>54</volume>(<issue>6</issue>):<fpage>639</fpage>&#8208;<lpage>650</lpage>.<pub-id pub-id-type="pmid">25523214</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40262-014-0227-1</pub-id><pub-id pub-id-type="pmcid">PMC4450126</pub-id></mixed-citation></ref><ref id="psp412737-bib-0020"><label>20</label><mixed-citation publication-type="miscellaneous" id="psp412737-cit-0020"><collab collab-type="authors">US Food and Drug Administration</collab>
. <article-title>Qualaquin [product label]</article-title>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021799s011lbl.pdf." ext-link-type="uri">https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021799s011lbl.pdf.</ext-link> Published 2013. Accessed June 25, 2019.</mixed-citation></ref><ref id="psp412737-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="psp412737-cit-0021"><string-name name-style="western"><surname>Bosgra</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>van Eijkeren</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Bos</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Zeilmaker</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Slob</surname><given-names>W</given-names></string-name>. <article-title>An improved model to predict physiologically based model parameters and their inter&#8208;individual variability from anthropometry</article-title>. <source>Crit Rev Toxicol</source>. <year>2012</year>;<volume>42</volume>(<issue>9</issue>):<fpage>751</fpage>&#8208;<lpage>767</lpage>.<pub-id pub-id-type="pmid">22954170</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3109/10408444.2012.709225</pub-id></mixed-citation></ref><ref id="psp412737-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="psp412737-cit-0022"><string-name name-style="western"><surname>Silamut</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>White</surname><given-names>NJ</given-names></string-name>, <string-name name-style="western"><surname>Looareesuwan</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Warrell</surname><given-names>DA</given-names></string-name>. <article-title>Binding of quinine to plasma proteins in falciparum malaria</article-title>. <source>Am J Trop Med Hyg</source>. <year>1985</year>;<volume>34</volume>(<issue>4</issue>):<fpage>681</fpage>&#8208;<lpage>686</lpage>.<pub-id pub-id-type="pmid">3896000</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4269/ajtmh.1985.34.681</pub-id></mixed-citation></ref><ref id="psp412737-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="psp412737-cit-0023"><string-name name-style="western"><surname>Uehara</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Higuchi</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Yoneda</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Yamazaki</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Suemizu</surname><given-names>H</given-names></string-name>. <article-title>Expression and inducibility of cytochrome P450s in human hepatocytes isolated from chimeric mice with humanised livers</article-title>. <source>Xenobiotica</source>. <year>2019</year>;<volume>49</volume>(<issue>6</issue>):<fpage>678</fpage>&#8208;<lpage>687</lpage>.<pub-id pub-id-type="pmid">29969338</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/00498254.2018.1495346</pub-id></mixed-citation></ref><ref id="psp412737-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="psp412737-cit-0024"><string-name name-style="western"><surname>Vermet</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Raoust</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Ngo</surname><given-names>R</given-names></string-name>, et al. <article-title>Evaluation of normalization methods to predict CYP3A4 induction in six fully characterized cryopreserved human hepatocyte preparations and HepaRG cells</article-title>. <source>Drug Metab Dispos</source>. <year>2016</year>;<volume>44</volume>(<issue>1</issue>):<fpage>50</fpage>&#8208;<lpage>60</lpage>.<pub-id pub-id-type="pmid">26467767</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/dmd.115.065581</pub-id></mixed-citation></ref><ref id="psp412737-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="psp412737-cit-0025"><string-name name-style="western"><surname>Supanaranond</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Davis</surname><given-names>TM</given-names></string-name>, <string-name name-style="western"><surname>Pukrittayakamee</surname><given-names>S</given-names></string-name>, et al. <article-title>Disposition of oral quinine in acute falciparum malaria</article-title>. <source>Eur J Clin Pharmacol</source>. <year>1991</year>;<volume>40</volume>(<issue>1</issue>):<fpage>49</fpage>&#8208;<lpage>52</lpage>.<pub-id pub-id-type="pmid">2060545</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/BF00315138</pub-id></mixed-citation></ref><ref id="psp412737-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="psp412737-cit-0026"><string-name name-style="western"><surname>Strauch</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Dressman</surname><given-names>JB</given-names></string-name>, <string-name name-style="western"><surname>Shah</surname><given-names>VP</given-names></string-name>, <string-name name-style="western"><surname>Kopp</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Polli</surname><given-names>JE</given-names></string-name>, <string-name name-style="western"><surname>Barends</surname><given-names>DM</given-names></string-name>. <article-title>Biowaiver monographs for immediate&#8208;release solid oral dosage forms: Quinine sulfate</article-title>. <source>J Pharm Sci</source>. <year>2012</year>;<volume>101</volume>(<issue>2</issue>):<fpage>499</fpage>&#8208;<lpage>508</lpage>.<pub-id pub-id-type="pmid">22081435</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jps.22810</pub-id></mixed-citation></ref><ref id="psp412737-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="psp412737-cit-0027"><string-name name-style="western"><surname>Dua</surname><given-names>VK</given-names></string-name>, <string-name name-style="western"><surname>Sarin</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Prakash</surname><given-names>A</given-names></string-name>. <article-title>Determination of quinine in serum, plasma, red blood cells and whole blood in healthy and Plasmodium falciparum malaria cases by high&#8208;performance liquid chromatography</article-title>. <source>J Chromatogr</source>. <year>1993</year>;<volume>614</volume>(<issue>1</issue>):<fpage>87</fpage>&#8208;<lpage>93</lpage>.<pub-id pub-id-type="pmid">8496290</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0378-4347(93)80226-t</pub-id></mixed-citation></ref><ref id="psp412737-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="psp412737-cit-0028"><string-name name-style="western"><surname>Ehrnebo</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Odar&#8208;Cederlof</surname><given-names>I</given-names></string-name>. <article-title>Binding of amobarbital, pentobarbital and diphenylhydantoin to blood cells and plasma proteins in healthy volunteers and uraemic patients</article-title>. <source>Eur J Clin Pharmacol</source>. <year>1975</year>;<volume>8</volume>(<issue>6</issue>):<fpage>445</fpage>&#8208;<lpage>453</lpage>.<pub-id pub-id-type="pmid">1233247</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/BF00562320</pub-id></mixed-citation></ref><ref id="psp412737-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="psp412737-cit-0029"><string-name name-style="western"><surname>Bender</surname><given-names>AD</given-names></string-name>, <string-name name-style="western"><surname>Post</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Meier</surname><given-names>JP</given-names></string-name>, <string-name name-style="western"><surname>Higson</surname><given-names>JE</given-names></string-name>, <string-name name-style="western"><surname>Reichard</surname><given-names>G</given-names></string-name>. <article-title>Plasma protein binding of drugs as a function of age in adult human subjects</article-title>. <source>J Pharm Sci</source>. <year>1975</year>;<volume>64</volume>(<issue>10</issue>):<fpage>1711</fpage>&#8208;<lpage>1713</lpage>.<pub-id pub-id-type="pmid">1185544</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jps.2600641030</pub-id></mixed-citation></ref><ref id="psp412737-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="psp412737-cit-0030"><string-name name-style="western"><surname>Shou</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Hayashi</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Pan</surname><given-names>Y</given-names></string-name>, et al. <article-title>Modeling, prediction, and in vitro in vivo correlation of CYP3A4 induction</article-title>. <source>Drug Metab Dispos</source>. <year>2008</year>;<volume>36</volume>(<issue>11</issue>):<fpage>2355</fpage>&#8208;<lpage>2370</lpage>.<pub-id pub-id-type="pmid">18669588</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/dmd.108.020602</pub-id></mixed-citation></ref><ref id="psp412737-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="psp412737-cit-0031"><string-name name-style="western"><surname>Xu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Hayashi</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Shou</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Skiles</surname><given-names>GL</given-names></string-name>. <article-title>Simulation of clinical drug&#8208;drug interactions from hepatocyte CYP3A4 induction data and its potential utility in trial designs</article-title>. <source>Drug Metab Dispos</source>. <year>2011</year>;<volume>39</volume>(<issue>7</issue>):<fpage>1139</fpage>&#8208;<lpage>1148</lpage>.<pub-id pub-id-type="pmid">21441468</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/dmd.111.038067</pub-id></mixed-citation></ref><ref id="psp412737-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="psp412737-cit-0032"><string-name name-style="western"><surname>White</surname><given-names>NJ</given-names></string-name>, <string-name name-style="western"><surname>Looareesuwan</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Warrell</surname><given-names>DA</given-names></string-name>, <string-name name-style="western"><surname>Warrell</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>Bunnag</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Harinasuta</surname><given-names>T</given-names></string-name>. <article-title>Quinine pharmacokinetics and toxicity in cerebral and uncomplicated Falciparum malaria</article-title>. <source>Am J Med</source>. <year>1982</year>;<volume>73</volume>(<issue>4</issue>):<fpage>564</fpage>&#8208;<lpage>572</lpage>.<pub-id pub-id-type="pmid">6751085</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0002-9343(82)90337-0</pub-id></mixed-citation></ref><ref id="psp412737-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="psp412737-cit-0033"><string-name name-style="western"><surname>Varma</surname><given-names>MV</given-names></string-name>, <string-name name-style="western"><surname>Gardner</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Steyn</surname><given-names>SJ</given-names></string-name>, et al. <article-title>pH&#8208;Dependent solubility and permeability criteria for provisional biopharmaceutics classification (BCS and BDDCS) in early drug discovery</article-title>. <source>Mol Pharm</source>. <year>2012</year>;<volume>9</volume>(<issue>5</issue>):<fpage>1199</fpage>&#8208;<lpage>1212</lpage>.<pub-id pub-id-type="pmid">22489626</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/mp2004912</pub-id></mixed-citation></ref><ref id="psp412737-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="psp412737-cit-0034"><string-name name-style="western"><surname>Zhao</surname><given-names>XJ</given-names></string-name>, <string-name name-style="western"><surname>Ishizaki</surname><given-names>T</given-names></string-name>. <article-title>A further interaction study of quinine with clinically important drugs by human liver microsomes: determinations of inhibition constant (Ki) and type of inhibition</article-title>. <source>Eur J Drug Metab Pharmacokinet</source>. <year>1999</year>;<volume>24</volume>(<issue>3</issue>):<fpage>272</fpage>&#8208;<lpage>278</lpage>.<pub-id pub-id-type="pmid">10716067</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/BF03190031</pub-id></mixed-citation></ref><ref id="psp412737-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="psp412737-cit-0035"><string-name name-style="western"><surname>Sahi</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Shord</surname><given-names>SS</given-names></string-name>, <string-name name-style="western"><surname>Lindley</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Ferguson</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>LeCluyse</surname><given-names>EL</given-names></string-name>. <article-title>Regulation of cytochrome P450 2C9 expression in primary cultures of human hepatocytes</article-title>. <source>J Biochem Mol Toxicol</source>. <year>2009</year>;<volume>23</volume>(<issue>1</issue>):<fpage>43</fpage>&#8208;<lpage>58</lpage>.<pub-id pub-id-type="pmid">19202563</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jbt.20264</pub-id></mixed-citation></ref><ref id="psp412737-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="psp412737-cit-0036"><string-name name-style="western"><surname>Salako</surname><given-names>LA</given-names></string-name>, <string-name name-style="western"><surname>Sowunmi</surname><given-names>A</given-names></string-name>. <article-title>Disposition of quinine in plasma, red blood cells and saliva after oral and intravenous administration to healthy adult Africans</article-title>. <source>Eur J Clin Pharmacol</source>. <year>1992</year>;<volume>42</volume>(<issue>2</issue>):<fpage>171</fpage>&#8208;<lpage>174</lpage>.<pub-id pub-id-type="pmid">1618248</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/BF00278479</pub-id></mixed-citation></ref><ref id="psp412737-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="psp412737-cit-0037"><string-name name-style="western"><surname>White</surname><given-names>NJ</given-names></string-name>, <string-name name-style="western"><surname>Looareesuwan</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Warrell</surname><given-names>DA</given-names></string-name>, et al. <article-title>Quinine loading dose in cerebral malaria</article-title>. <source>Am J Trop Med Hyg</source>. <year>1983</year>;<volume>32</volume>(<issue>1</issue>):<fpage>1</fpage>&#8208;<lpage>5</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.4269/ajtmh.1983.32.1</pub-id><pub-id pub-id-type="pmid">6337514</pub-id></mixed-citation></ref><ref id="psp412737-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="psp412737-cit-0038"><string-name name-style="western"><surname>Davis</surname><given-names>TM</given-names></string-name>, <string-name name-style="western"><surname>White</surname><given-names>NJ</given-names></string-name>, <string-name name-style="western"><surname>Looareesuwan</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Silamut</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Warrell</surname><given-names>DA</given-names></string-name>. <article-title>Quinine pharmacokinetics in cerebral malaria: predicted plasma concentrations after rapid intravenous loading using a two&#8208;compartment model</article-title>. <source>Trans R Soc Trop Med Hyg</source>. <year>1988</year>;<volume>82</volume>(<issue>4</issue>):<fpage>542</fpage>&#8208;<lpage>547</lpage>.<pub-id pub-id-type="pmid">3256106</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0035-9203(88)90498-1</pub-id></mixed-citation></ref><ref id="psp412737-bib-0039"><label>39</label><mixed-citation publication-type="journal" id="psp412737-cit-0039"><string-name name-style="western"><surname>Nelson</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Powell</surname><given-names>JR</given-names></string-name>, <string-name name-style="western"><surname>Conrad</surname><given-names>K</given-names></string-name>, et al. <article-title>Phenobarbital pharmacokinetics and bioavailability in adults</article-title>. <source>J Clin Pharmacol</source>. <year>1982</year>;<volume>22</volume>(<issue>2&#8211;3</issue>):<fpage>141</fpage>&#8208;<lpage>148</lpage>.<pub-id pub-id-type="pmid">7068937</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/j.1552-4604.1982.tb02662.x</pub-id></mixed-citation></ref><ref id="psp412737-bib-0040"><label>40</label><mixed-citation publication-type="journal" id="psp412737-cit-0040"><string-name name-style="western"><surname>Saeheng</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Na&#8208;Bangchang</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Karbwang</surname><given-names>J</given-names></string-name>. <article-title>Utility of physiologically based pharmacokinetic (PBPK) modeling in oncology drug development and its accuracy: a systematic review</article-title>. <source>Eur J Clin Pharmacol</source>. <year>2018</year>;<volume>74</volume>(<issue>11</issue>):<fpage>1365</fpage>&#8208;<lpage>1376</lpage>.<pub-id pub-id-type="pmid">29978293</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00228-018-2513-6</pub-id></mixed-citation></ref><ref id="psp412737-bib-0041"><label>41</label><mixed-citation publication-type="journal" id="psp412737-cit-0041"><string-name name-style="western"><surname>Thanachartwet</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Desakorn</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Sahassananda</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Kyaw Win</surname><given-names>KK</given-names></string-name>, <string-name name-style="western"><surname>Supaporn</surname><given-names>T</given-names></string-name>. <article-title>Acute renal failure in patients with severe falciparum Malaria: using the WHO 2006 and RIFLE criteria</article-title>. <source>Int J Nephrol</source>. <year>2013</year>;<volume>2013</volume>:<fpage>841518</fpage>.<pub-id pub-id-type="pmid">23431442</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2013/841518</pub-id><pub-id pub-id-type="pmcid">PMC3569909</pub-id></mixed-citation></ref><ref id="psp412737-bib-0042"><label>42</label><mixed-citation publication-type="journal" id="psp412737-cit-0042"><string-name name-style="western"><surname>Kokwaro</surname><given-names>GO</given-names></string-name>, <string-name name-style="western"><surname>Ogutu</surname><given-names>BR</given-names></string-name>, <string-name name-style="western"><surname>Muchohi</surname><given-names>SN</given-names></string-name>, <string-name name-style="western"><surname>Otieno</surname><given-names>GO</given-names></string-name>, <string-name name-style="western"><surname>Newton</surname><given-names>CR</given-names></string-name>. <article-title>Pharmacokinetics and clinical effect of phenobarbital in children with severe falciparum malaria and convulsions</article-title>. <source>Br J Clin Pharmacol</source>. <year>2003</year>;<volume>56</volume>(<issue>4</issue>):<fpage>453</fpage>&#8208;<lpage>457</lpage>.<pub-id pub-id-type="pmid">12968992</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1046/j.1365-2125.2003.01951.x</pub-id><pub-id pub-id-type="pmcid">PMC1884365</pub-id></mixed-citation></ref><ref id="psp412737-bib-0043"><label>43</label><mixed-citation publication-type="journal" id="psp412737-cit-0043"><string-name name-style="western"><surname>Mohapatra</surname><given-names>MKD</given-names></string-name>, <string-name name-style="western"><surname>Dash</surname><given-names>LK</given-names></string-name>, <string-name name-style="western"><surname>Mishra</surname><given-names>NR</given-names></string-name>, <string-name name-style="western"><surname>Agrawala</surname><given-names>RK</given-names></string-name>. <article-title>Profile of seizures in adult falciparum malaria and clinical efficacy of phenytoin sodium for control seizures</article-title>. <source>Asian Pac J Trop Dis</source>. <year>2012</year>;<volume>2</volume>(<issue>suppl 2</issue>):<fpage>S558</fpage>&#8208;<lpage>S562</lpage>.</mixed-citation></ref><ref id="psp412737-bib-0044"><label>44</label><mixed-citation publication-type="journal" id="psp412737-cit-0044"><string-name name-style="western"><surname>Patsalos</surname><given-names>PN</given-names></string-name>, <string-name name-style="western"><surname>Berry</surname><given-names>DJ</given-names></string-name>, <string-name name-style="western"><surname>Bourgeois</surname><given-names>BF</given-names></string-name>, et al. <article-title>Antiepileptic drugs&#8211;best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring. ILAE Commission on Therapeutic Strategies</article-title>. <source>Epilepsia</source>. <year>2008</year>;<volume>49</volume>(<issue>7</issue>):<fpage>1239</fpage>&#8208;<lpage>1276</lpage>.<pub-id pub-id-type="pmid">18397299</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1528-1167.2008.01561.x</pub-id></mixed-citation></ref><ref id="psp412737-bib-0045"><label>45</label><mixed-citation publication-type="journal" id="psp412737-cit-0045"><string-name name-style="western"><surname>Sukasem</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Tunthong</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Chamnanphon</surname><given-names>M</given-names></string-name>, et al. <article-title>CYP2C19 polymorphisms in the Thai population and the clinical response to clopidogrel in patients with atherothrombotic&#8208;risk factors</article-title>. <source>Pharmgenomics Pers Med</source>. <year>2013</year>;<volume>6</volume>:<fpage>85</fpage>&#8208;<lpage>91</lpage>.<pub-id pub-id-type="pmid">24019752</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/PGPM.S42332</pub-id><pub-id pub-id-type="pmcid">PMC3760447</pub-id></mixed-citation></ref><ref id="psp412737-bib-0046"><label>46</label><mixed-citation publication-type="journal" id="psp412737-cit-0046"><string-name name-style="western"><surname>Sangviroon</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Panomvana</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Tassaneeyakul</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Namchaisiri</surname><given-names>J</given-names></string-name>. <article-title>Pharmacokinetic and pharmacodynamic variation associated with VKORC1 and CYP2C9 polymorphisms in Thai patients taking warfarin</article-title>. <source>Drug Metab Pharmacokinet</source>. <year>2010</year>;<volume>25</volume>(<issue>6</issue>):<fpage>531</fpage>&#8208;<lpage>538</lpage>.<pub-id pub-id-type="pmid">20930419</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2133/dmpk.dmpk-10-rg-059</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>